<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">106736</article-id>
<article-id pub-id-type="doi">10.7554/eLife.106736</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.106736.1</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.1</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Hyperpolarized <sup>13</sup>C metabolic imaging detects long-lasting metabolic alterations following mild repetitive traumatic brain injury</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0305-1631</contrib-id>
<name>
<surname>Guglielmetti</surname>
<given-names>Caroline</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Qiao</surname>
<given-names>Kai</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tiret</surname>
<given-names>Brice</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7708-6549</contrib-id>
<name>
<surname>Ozen</surname>
<given-names>Mustafa</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Krukowski</surname>
<given-names>Karen</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nolan</surname>
<given-names>Amber</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Paladini</surname>
<given-names>Maria Serena</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lopez</surname>
<given-names>Carlos F</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2110-4613</contrib-id>
<name>
<surname>Chaumeil</surname>
<given-names>Myriam M</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
<email xlink:href="mailto:myriam.chaumeil@ucsf.edu">myriam.chaumeil@ucsf.edu</email>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Rosi</surname>
<given-names>Susanna</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A8">8</xref>
<xref ref-type="aff" rid="A9">9</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
<email xlink:href="mailto:srosi@altoslabs.com">srosi@altoslabs.com</email>
</contrib>
<aff id="A1"><label>1.</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Department of Physical Therapy and Rehabilitation Science, University of California, San Francisco</institution></institution-wrap>, <city>San Francisco</city>, <country country="US">United States</country></aff>
<aff id="A2"><label>2.</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Department of Radiology and Biomedical Imaging, University of California, San Francisco</institution></institution-wrap>, <city>San Francisco</city>, <country country="US">United States</country></aff>
<aff id="A3"><label>3.</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05467hx49</institution-id><institution>Bay Area Institute of Science, Altos Labs</institution></institution-wrap>, <city>Redwood City</city>, <country country="US">United States</country></aff>
<aff id="A4"><label>4.</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Brain and Spinal Injury Center, University of California, San Francisco</institution></institution-wrap>, <city>San Francisco</city>, <country country="US">United States</country></aff>
<aff id="A5"><label>5.</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04w7skc03</institution-id><institution>Knoebel Institute for Healthy Aging, University of Denver</institution></institution-wrap>, <city>Denver</city>, <country country="US">United States</country></aff>
<aff id="A6"><label>6.</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05467hx49</institution-id><institution>Bay Area Institute of Science, Altos Labs</institution></institution-wrap>, <city>Redwood City</city>, <country country="US">United States</country></aff>
<aff id="A7"><label>7.</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cvxb145</institution-id><institution>Department of Laboratory Medicine and Pathology, University of Washington</institution></institution-wrap>, <city>Seattle</city>, <country country="US">United States</country></aff>
<aff id="A8"><label>8.</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Weill institute for Neuroscience, University of California, San Francisco</institution></institution-wrap>, <city>San Francisco</city>, <country country="US">United States</country></aff>
<aff id="A9"><label>9.</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Department of Neurological Surgery, University of California, San Francisco</institution></institution-wrap>, <city>San Francisco</city>, <country country="US">United States</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Jbabdi</surname>
<given-names>Saad</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>University of Oxford</institution>
</institution-wrap>
<city>Oxford</city>
<country>United Kingdom</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Wong</surname>
<given-names>Ma-Li</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>State University of New York Upstate Medical University</institution>
</institution-wrap>
<city>Syracuse</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<fn id="FN1"><label>*</label><p>Equal contribution, corresponding authors.</p></fn>
<fn id="FN2" fn-type="coi-statement"><p><bold>Competing interests</bold> The authors declare that they have no competing interests.</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>15</day>
<month>04</month>
<year>2025</year>
</pub-date>
<pub-date date-type="original-publication" iso-8601-date="2025-06-23">
<day>23</day>
<month>06</month>
<year>2025</year>
</pub-date>
<volume>14</volume>
<elocation-id>RP106736</elocation-id>
<history><date date-type="sent-for-review" iso-8601-date="2025-04-02">
<day>02</day>
<month>04</month>
<year>2025</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2023-08-14">
<day>14</day>
<month>08</month>
<year>2023</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.21203/rs.3.rs-3166656/v1"/>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2025, Guglielmetti et al</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Guglielmetti et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-106736-v1.pdf"/>
<abstract>
<title>Abstract</title>
<p>Career athletes, active military, and head trauma victims are at increased risk for mild repetitive traumatic brain injury (rTBI), a condition that contributes to the development of epilepsy and neurodegenerative diseases. Standard clinical imaging fails to identify rTBI-induced lesions, and novel non-invasive methods are needed. Here, we evaluated if hyperpolarized <sup>13</sup>C magnetic resonance spectroscopic imaging (HP <sup>13</sup>C MRSI) could detect long-lasting changes in brain metabolism 3.5 months post-injury in a rTBI mouse model. Our results show that this metabolic imaging approach can detect changes in cortical metabolism at that timepoint, whereas multimodal MR imaging did not detect any structural or contrast alterations. Using Machine Learning, we further show that HP <sup>13</sup>C MRSI parameters can help classify rTBI vs. Sham and predict long-term rTBI-induced behavioral outcomes. Altogether, our study demonstrates the potential of metabolic imaging to improve detection, classification and outcome prediction of previously undetected rTBI.</p>
</abstract>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Individuals subject to frequent concussions such as career athletes (e.g. football players, boxers), accidental head trauma victims, domestic abuse victims, or active military are some of the population at risk for mild repetitive traumatic brain injury (rTBI). Indeed, rTBI is being steadily recognized as a risk factor for the development of epilepsy and neurodegenerative diseases, particularly chronic traumatic encephalopathy (CTE)<sup><xref ref-type="bibr" rid="c1">1</xref>, <xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c3">3</xref></sup>. However, to date, non-invasive diagnostic biomarkers of rTBI are lacking. In particular, clinical computed tomography (CT) and magnetic resonance imaging (MRI), the standard imaging methods for trauma patients, are unable to detect rTBI-induced pathology<sup><xref ref-type="bibr" rid="c4">4</xref>, <xref ref-type="bibr" rid="c5">5</xref>, <xref ref-type="bibr" rid="c6">6</xref></sup>. This lack of imaging techniques hampers proper diagnosis and appropriate clinical care, as a result new approaches are critically needed.</p>
<p>To further our understanding of rTBI, several models were developed over the past years<sup><xref ref-type="bibr" rid="c7">7</xref>, <xref ref-type="bibr" rid="c8">8</xref></sup>. The closed-head impact model of engineered rotational acceleration (CHIMERA) device was designed to deliver multiple subconcussive mild TBI in a controlled and reproducible manner<sup><xref ref-type="bibr" rid="c9">9</xref></sup>. CHIMERA-induced rTBI has been shown to lead to reproducible pathological and behavioral changes up to several months following impacts<sup><xref ref-type="bibr" rid="c10">10</xref></sup>, mirroring the long-term effects of rTBI seen in the clinic (review by McNamara <italic>et al</italic>.<sup><xref ref-type="bibr" rid="c11">11</xref></sup>). Only a few studies have investigated the use of magnetic resonance imaging (MRI) to detect CHIMERA-induced rTBI. Diffusion MRI, which is sensitive to water diffusion in tissue and changes in tissue microstructure, detected subtle differences in rTBI animals at 7 days following injury and in the optic tract, brachium of the superior colliculus, corpus callosum and hippocampus regions<sup><xref ref-type="bibr" rid="c12">12</xref>, <xref ref-type="bibr" rid="c13">13</xref></sup>; however, long-lasting changes were not studied. T2-weighted MRI, which is sensitive to changes in tissue microstructure, edema, and myelination, did not detect signs of brain injury at 7 days and 40 days post-injury<sup><xref ref-type="bibr" rid="c10">10</xref>, <xref ref-type="bibr" rid="c12">12</xref></sup>. All these studies are in line with clinical findings, and further highlight the need for more sensitive approaches to detect and monitor long-term brain changes after rTBI.</p>
<p>Metabolic impairment following TBI has been well documented in patients and animal models in the hours following TBI using <sup>13</sup>C-labelled substrates infusion and metabolomics approaches (reviews by Jalloh, Dermers-Marcil, and Carpenter<sup><xref ref-type="bibr" rid="c14">14</xref>, <xref ref-type="bibr" rid="c15">15</xref>, <xref ref-type="bibr" rid="c16">16</xref></sup>). Notably, cerebral microdialysis studies have identified that the lactate / pyruvate ratio (Lac/Pyr) parameter is associated with poor outcome<sup><xref ref-type="bibr" rid="c17">17</xref>, <xref ref-type="bibr" rid="c18">18</xref></sup>. However, as cerebral microdialysis is an invasive method, its use at chronic timepoints following TBI, or in closed head injury and concussion is not feasible. Hyperpolarized <sup>13</sup>C magnetic resonance spectroscopic imaging (HP <sup>13</sup>C MRSI) is a unique technology that allows to measure metabolic fluxes <italic>in vivo,</italic> and to compute lactate / pyruvate ratio values as well. HP <sup>13</sup>C MRSI applications have been extensively described in the oncology field<sup><xref ref-type="bibr" rid="c19">19</xref>, <xref ref-type="bibr" rid="c20">20</xref></sup>, and its use is emerging to probe brain metabolism in health and diseases<sup><xref ref-type="bibr" rid="c21">21</xref></sup>. HP <sup>13</sup>C MRSI of [1-<sup>13</sup>C]pyruvate enables to monitor the conversion of this key metabolite into its product(s) [1-<sup>13</sup>C]lactate and/or [<sup>13</sup>C]bicarbonate in the brain, which provides unprecedented metabolic information<sup><xref ref-type="bibr" rid="c22">22</xref>, <xref ref-type="bibr" rid="c23">23</xref></sup>. Prior studies of moderate TBI have shown changes in the HP <sup>13</sup>C lactate / pyruvate ratio (HP <sup>13</sup>C Lac/Pyr), and HP <sup>13</sup>C bicarbonate / lactate ratio at early timepoints (4 hours up to 7 days) following injury in preclinical models and in patients<sup><xref ref-type="bibr" rid="c24">24</xref>, <xref ref-type="bibr" rid="c25">25</xref>, <xref ref-type="bibr" rid="c26">26</xref></sup>, demonstrating the potential value of this technique. Furthermore, recent studies have combined injection of HP [1-<sup>13</sup>C]pyruvate with HP [<sup>13</sup>C]urea, a metabolically inactive probe, to simultaneously evaluate the pyruvate to lactate flux and tissue perfusion, respectively<sup><xref ref-type="bibr" rid="c27">27</xref>, <xref ref-type="bibr" rid="c28">28</xref>, <xref ref-type="bibr" rid="c29">29</xref>, <xref ref-type="bibr" rid="c30">30</xref>, <xref ref-type="bibr" rid="c31">31</xref></sup>. However, it remains to be determined whether HP <sup>13</sup>C MRSI of HP [1- <sup>13</sup>C]pyruvate might be useful to the detection of rTBI at chronic timepoints, and inform on potential mechanism of metabolic injury. Furthermore, co-injection of HP [1-<sup>13</sup>C]pyruvate and HP [<sup>13</sup>C]urea has never been tested in any TBI model or patient.</p>
<p>Here, we questioned if advanced imaging approaches that have never been applied to the study of rTBI could detect long-lasting alterations following rTBI in the CHIMERA model. In addition to the above described HP <sup>13</sup>C MRSI of HP [1-<sup>13</sup>C]pyruvate and HP [<sup>13</sup>C]urea, we also evaluated Susceptibility-weighted imaging (SWI) and T<sub>1</sub> mapping. SWI is an MRI method particularly sensitive to iron that can inform on venous deoxygenated blood and iron deposition in tissue, and which has proven very valuable to identify microbleeds in TBI, but has not yet been investigated in the CHIMERA model<sup><xref ref-type="bibr" rid="c32">32</xref>, <xref ref-type="bibr" rid="c33">33</xref></sup>. Recent reports have highlighted the potential of T<sub>1</sub> mapping to detect oxidative stress in the rodent brain<sup><xref ref-type="bibr" rid="c34">34</xref></sup>, and thus this technique holds great potential to detect the production of reactive oxygen species that may occur following diffuse axonal injury and inflammatory processes observed in the CHIMERA model<sup><xref ref-type="bibr" rid="c11">11</xref></sup>.</p>
<p>As shown in <xref ref-type="fig" rid="fig1">Fig. 1</xref>, we induced rTBI in two-month old male mice using the CHIMERA apparatus, tested risk-taking behavior 3 months post rTBI, and performed four MRI-based scans. We investigated the potential of <sup>13</sup>C MRSI of HP [1-<sup>13</sup>C]pyruvate and [<sup>13</sup>C]urea to detect metabolic and tissue perfusion impairment, T<sub>2</sub>-weighted MRI to assess structural changes (as clinical standard of MR imaging), T<sub>1</sub>-mapping to evaluate tissue microstructure alterations and oxidative stress, and SWI MRI to detect changes in tissue microstructure, microbleed and tissue oxygenation following rTBI. Last, brain tissue was collected to evaluate changes in enzymes activity and transporter protein expression. Given the multidimensional nature of the data, we used a Machine Learning (ML) approach to identify how measured parameters could best predict changes in risk-taking behavior and HP 13C MRSI.</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1</label>
<caption><title>Study outline.</title>
<p>Experimental timeline of the study. Two-month old male mice received a rTBI using the CHIMERA device or underwent a Sham procedure (no impact). Risk-taking behavior was evaluated at 3 months post-injury using the Elevated Plus Maze. MR imaging was performed 3.5 months after Sham or rTBI, and included HP <sup>13</sup>C MRSI, T<sub>2</sub>-weighted MRI, T<sub>1</sub> mapping MRI, and SWI MRI. Tissue was collected 4 months after Sham or rTBI procedures to evaluate PDH and LDH activities, and expression of MCT1 and MCT4. ML analyses methods were used to identify the best classifiers between rTBI and Sham, and the best predictors of the risk-taking behavior and HP <sup>13</sup>C Lac/Pyr in the cortex.</p></caption>
<graphic xlink:href="3166656v1_fig1.tif" mime-subtype="tif" mimetype="image"/>
</fig>
</sec>
<sec id="s2" sec-type="results">
<title>Results</title>
<sec id="s2-1">
<title>HP <sup>13</sup>C MRSI detects long-lasting metabolic alterations following rTBI</title>
<p>We investigated whether HP <sup>13</sup>C MRSI could be used as a non-invasive tool to detect rTBI-induced long-lasting changes, and specifically to question whether metabolic alterations are present at chronic time points following injury.</p>
<p>Following intravenous co-injection of HP [1-<sup>13</sup>C]pyruvate and HP [<sup>13</sup>C]urea, we observed signals from both substrates, as well as from the metabolic product HP [1-<sup>13</sup>C]lactate in the cortex (<xref ref-type="fig" rid="fig2">Fig. 2.<bold>a</bold></xref>) and subcortex (<xref ref-type="fig" rid="fig2">Fig. 2.<bold>b</bold></xref>) of Sham and rTBI mice at 3.5 months post-injury. Upon quantification, we observed significant metabolic differences between the cortex of rTBI compared to Sham mice: HP [1-<sup>13</sup>C]lactate levels were 1.09 fold lower in rTBI (<xref ref-type="fig" rid="fig3">Fig. 3.<bold>a</bold></xref>, p = 0.0073), HP [1-<sup>13</sup>C]pyruvate levels were 1.05 fold higher (<xref ref-type="fig" rid="fig3">Fig. 3.<bold>b</bold></xref>, p = 0.0073), and HP <sup>13</sup>C Lac/Pyr was 1.15 fold lower (<xref ref-type="fig" rid="fig3">Fig. 3.<bold>c</bold></xref>, p = 0.0071). No significant differences in HP [<sup>13</sup>C]urea levels were observed in the cortical area (<xref ref-type="fig" rid="fig3">Fig. 3.<bold>c</bold></xref>), although a trend towards lower HP [<sup>13</sup>C]urea levels in rTBI was observed (p = 0.0794). In subcortical areas, we did not detect any differences in HP [1- <sup>13</sup>C]lactate, HP [1-<sup>13</sup>C]pyruvate, HP <sup>13</sup>C Lac/Pyr and HP [<sup>13</sup>C]urea between rTBI and Sham mice (<xref ref-type="fig" rid="fig3">Fig. 3.<bold>e-h</bold></xref>). In agreement with the metabolic quantifications, HP <sup>13</sup>C heatmaps clearly show lower HP [1- <sup>13</sup>C]lactate, higher HP [1-<sup>13</sup>C]pyruvate and lower HP <sup>13</sup>C Lac/Pyr in the cortex of rTBI mice (<xref ref-type="fig" rid="fig3">Fig. 3.<bold>i</bold></xref>). Altogether, our results indicate that HP <sup>13</sup>C MRSI can detect region-specific long-lasting metabolic changes following mild rTBI.</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Figure 2</label>
<caption><title>HP <sup>13</sup>C spectra following co-injection of HP [1-<sup>13</sup>C]pyruvate and [<sup>13</sup>C]urea.</title>
<p>Representative T<sub>2</sub>-weighted MR image overlaid with the grid used for HP <sup>13</sup>C MRSI acquisitions. Representative <sup>13</sup>C spectra showing HP [1-<sup>13</sup>C]pyruvate, HP [<sup>13</sup>C]urea and HP [1-<sup>13</sup>C]lactate in the (a) cortex (red voxel) and (b) subcortex (red voxel) for a Sham and a rTBI mouse.</p></caption>
<graphic xlink:href="3166656v1_fig2.tif" mime-subtype="tif" mimetype="image"/>
</fig>
<fig id="fig3" position="float" fig-type="figure">
<label>Figure 3</label>
<caption><title>HP <sup>13</sup>C MRSI detects long-lasting metabolic alterations following rTBI.</title>
<p>Quantitative analyses of <bold>(a)</bold> HP [1-<sup>13</sup>C]lactate levels, <bold>(b)</bold> HP [1-<sup>13</sup>C]pyruvate levels, <bold>(c)</bold> HP <sup>13</sup>C Lac/Pyr, and <bold>(d)</bold> HP [<sup>13</sup>C]urea for the cortex (highlighted red voxels), revealed lower HP [1-<sup>13</sup>C]lactate levels (p = 0.0073), higher HP [1-<sup>13</sup>C]pyruvate levels (p = 0.0073), and lower HP <sup>13</sup>C Lac/Pyr (p = 0.0071) in rTBI compared to Sham mice. In contrast, quantitative analyses of <bold>(e)</bold> HP [1-<sup>13</sup>C]lactate levels, <bold>(f)</bold> HP [1-<sup>13</sup>C]pyruvate levels, <bold>(g)</bold> HP <sup>13</sup>C Lac/Pyr, and <bold>(h)</bold> HP [<sup>13</sup>C]urea for the subcortex (highlighted red voxels), did not detect differences between rTBI and Sham mice. (i) Representative HP <sup>13</sup>C heatmaps for a Sham and a rTBI mouse, highlighting lower HP [1-<sup>13</sup>C]lactate, higher HP [1-<sup>13</sup>C]pyruvate and lower HP <sup>13</sup>C Lac/Pyr in cortical areas in rTBI mice. <italic>N=</italic> 9 rTBI and 10 Sham mice. Unpaired <italic>t</italic>-test <italic>**p ≤ 0.01</italic>);data are expressed as means ± SD.</p></caption>
<graphic xlink:href="3166656v1_fig3.tif" mime-subtype="tif" mimetype="image"/>
</fig>
</sec>
<sec id="s2-2">
<title>Multimodal MRI does not detect long-lasting effect of injury in rTBI</title>
<p>We evaluated whether a comprehensive multimodal MRI approach could detect changes between rTBI and Sham mice at 3.5 months post-injury, when metabolic alterations where detected by HP <sup>13</sup>C MRSI.</p>
<p>We first used T<sub>2</sub>-weighted MRI, the clinical standard of MRI approach, that is sensitive to inflammation and/or changes in myelin content. We found that T<sub>2</sub> signal intensities were not different between rTBI and Sham mice in any of the regions studied (prefrontal cortex, cortex, hippocampus and thalamus (subcortex)) (<xref ref-type="fig" rid="fig4">Fig. 4.<bold>a-b</bold></xref>). In addition, we did not detect any differences in brain region volumes between groups (<xref ref-type="fig" rid="fig6">Supplementary Fig. 1</xref>). Next, we used a T<sub>1</sub> mapping sequence that was shown to be sensitive to changes in microstructure or alterations related to oxidative stress. Similar to the T<sub>2</sub> intensities, we did not observed any differences in the T<sub>1</sub> values in any of the region studied between rTBI and Sham mice (<xref ref-type="fig" rid="fig4">Fig. 4.<bold>c-d</bold></xref>). Lastly, a SWI sequence was used, as it is capable of detecting microbleeds as well as potential changes in oxygenation following injury. Once again, no differences in SWI values were observed between rTBI and Sham mice in any region (<xref ref-type="fig" rid="fig4">Fig. 4.<bold>e-f</bold></xref>). We did not detect any microbleed lesions in any of the studied animals.</p>
<fig id="fig4" position="float" fig-type="figure">
<label>Figure 4</label>
<caption><title>Multimodal MRI does not detect long-lasting effect of injury in rTBI.</title>
<p><bold>(a)</bold> Representative T<sub>2</sub>-weighted MRI data and corresponding manual brain masking. <bold>(b)</bold> Quantitative analyses of T<sub>2</sub>-weighted signal intensity revealed no significant differences for brain subregions between Sham and rTBI. <bold>(c)</bold> Representative T<sub>1</sub> map and corresponding manual brain masking. <bold>(d)</bold> Quantitative analyses of T<sub>1</sub> maps revealed no significant differences for brain subregions between Sham and rTBI. <bold>(e)</bold> Representative SWI data and corresponding manual brain masking. <bold>(f)</bold> Quantitative analyses of SWI intensity revealed no significant differences for brain subregions between Sham and rTBI. Brain masking color code: yellow: cortex, green: light blue: prefrontal cortex; hippocampus; dark blue: thalamus. <italic>N</italic>= 10 rTBI and 10 Sham mice. Unpaired <italic>t</italic>-test; data are expressed as means ± SD.</p></caption>
<graphic xlink:href="3166656v1_fig4.tif" mime-subtype="tif" mimetype="image"/>
</fig>
<p>Altogether, our results indicate that a comprehensive multimodal MRI approach combining T<sub>2</sub>-weighted MRI, T<sub>1</sub> mapping and SWI was not able to detect any signs of injury in rTBI mice at 3.5 months postinjury, unlike HP<sup>13</sup>C MRSI.</p>
</sec>
<sec id="s2-3">
<title>Disrupted enzymatic activity, but not transporter expression, is observed at chronic time points after rTBI</title>
<p>To further investigate potential underlying mechanisms responsible for the observed changes in HP <sup>13</sup>C MRSI readouts, we evaluated the activity of enzymes responsible for pyruvate conversion into its downstream metabolites and the expression of transporters that control the entry of pyruvate into cells and the efflux of metabolites outside of the cells.</p>
<p>In the brain, lactate dehydrogenase (LDH) converts pyruvate into lactate, and pyruvate dehydrogenase (PDH) controls pyruvate entry into the tricarboxylic cycle and its conversion into acetyl-coA. We observed that PDH was 1.6 fold lower in the prefrontal cortex and 1.7 fold lower in the cortex of rTBI compared to Sham mice (<xref ref-type="table" rid="tbl1">Table 1</xref>, p = 0.0044 and p = 0.0375, respectively). No differences in PDH were observed in subcortical areas that include the hippocampus and thalamus. The activity of LDH was not significantly different between rTBI and Sham mice for cortical and subcortical areas.</p>
<table-wrap id="tbl1" position="float" orientation="portrait">
<label>Table 1</label>
<caption><title>PDH and LDH enzyme activity.</title></caption>
<alternatives>
<graphic xlink:href="3166656v1_tbl1.tif" mime-subtype="tif" mimetype="image"/>
<table frame="box" rules="rows">
<thead>
<tr>
<th align="left" valign="top" colspan="2" rowspan="2"/>
<th align="left" valign="top" colspan="2">PDH activity</th>
<th align="left" valign="top" colspan="2">LDH activity</th>
</tr>
<tr>
<th align="left" valign="top">mean ± SD</th>
<th align="left" valign="top"><italic>P-value</italic></th>
<th align="left" valign="top">mean ± SD</th>
<th align="left" valign="top"><italic>P-value</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="2"><bold>Prefrontal cortex</bold></td>
<td align="left" valign="top">rTBI</td>
<td align="left" valign="top">0.0007 ± 0.0001</td>
<td align="left" valign="top"><bold>0.0044</bold> <xref ref-type="table-fn" rid="tfn3">(**)</xref></td>
<td align="left" valign="top">0.0070 ±0.0007</td>
<td align="left" valign="top"><italic>0.3345</italic></td>
</tr>
<tr>
<td align="left" valign="top">Sham</td>
<td align="left" valign="top">0.0011 ±0.0003</td>
<td align="left" valign="top"/>
<td align="left" valign="top">0.0078 ±0.0020</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" rowspan="2"><bold>Cortex</bold></td>
<td align="left" valign="top">rTBI</td>
<td align="left" valign="top">0.0012 ± 0.0005</td>
<td align="left" valign="top"><bold>0.0375</bold> <xref ref-type="table-fn" rid="tfn2">(*)</xref></td>
<td align="left" valign="top">0.0022 ±0.0004</td>
<td align="left" valign="top"><italic>0.5837</italic></td>
</tr>
<tr>
<td align="left" valign="top">Sham</td>
<td align="left" valign="top">0.002 ±0.0008</td>
<td align="left" valign="top"/>
<td align="left" valign="top">0.0023 ±0.0003</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" rowspan="2"><bold>Hippocampus</bold></td>
<td align="left" valign="top">rTBI</td>
<td align="left" valign="top">0.0074 ±0.003</td>
<td align="left" valign="top"><italic>0.4171</italic></td>
<td align="left" valign="top">0.0020 ±0.0002</td>
<td align="left" valign="top"><italic>0.1602</italic></td>
</tr>
<tr>
<td align="left" valign="top">Sham</td>
<td align="left" valign="top">0.0091 ±0.005</td>
<td align="left" valign="top"/>
<td align="left" valign="top">0.0023 ±0.0005</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" rowspan="2"><bold>Thalamus</bold></td>
<td align="left" valign="top">rTBI</td>
<td align="left" valign="top">0.00013 ±0.00003</td>
<td align="left" valign="top"><italic>0.6509</italic></td>
<td align="left" valign="top">0.0023 ±0.0004</td>
<td align="left" valign="top"><italic>0.1282</italic></td>
</tr>
<tr>
<td align="left" valign="top">Sham</td>
<td align="left" valign="top">0.00014± 0.00006</td>
<td align="left" valign="top"/>
<td align="left" valign="top">0.0021 ±0.0002</td>
<td align="left" valign="top"/>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="tfn1"><p>Unpaired t-test.</p></fn>
<fn id="tfn2"><label>*</label><p><italic>p</italic> &lt; 0.05,</p></fn>
<fn id="tfn3"><label>**</label><p><italic>p</italic> &lt; 0.01.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>As levels of HP metabolites and HP <sup>13</sup>C Lac/Pyr also depend on HP [1-13C]pyruvate intake by cells and on the efflux of HP [1-<sup>13</sup>C]lactate, we evaluated the expression of monocarboxylate transporters (MCTs). MCT1 is primarily responsible for pyruvate entry into the cell, and MCT4 is principaly involved in the efflux of lactate outside of the cell. Protein quantification of MCT1 and MCT4 performed for the prefrontal cortex, cortex, hippocampus and thalamus did not show any differences between rTBI and Sham mice (<xref ref-type="table" rid="tbl2">Table 2</xref>), indicating that the differences observed with HP <sup>13</sup>C MRSI are likely not due to MCT1 and MCT4 expression.</p>
<table-wrap id="tbl2" position="float" orientation="portrait">
<label>Table 2</label>
<caption><title>MCT1 and MCT4 protein expression.</title></caption>
<alternatives>
<graphic xlink:href="3166656v1_tbl2.tif" mime-subtype="tif" mimetype="image"/>
<table frame="box" rules="rows">
<thead>
<tr>
<th align="left" valign="top" colspan="2" rowspan="2"/>
<th align="left" valign="top" colspan="2">MCT1</th>
<th align="left" valign="top" colspan="2">MCT4</th>
</tr>
<tr>
<th align="left" valign="top">mean ± SD</th>
<th align="left" valign="top"><italic>P-value</italic></th>
<th align="left" valign="top">mean ± SD</th>
<th align="left" valign="top"><italic>P-value</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="2"><bold>Prefrontal cortex</bold></td>
<td align="left" valign="top">rTBI</td>
<td align="left" valign="top">1.3 ±0.31</td>
<td align="left" valign="top"><italic>0.0685</italic></td>
<td align="left" valign="top">1.59 ±0.72</td>
<td align="left" valign="top"><italic>0.1109</italic></td>
</tr>
<tr>
<td align="left" valign="top">Sham</td>
<td align="left" valign="top">1 ±0.32</td>
<td align="left" valign="top"/>
<td align="left" valign="top">1 ±0.54</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" rowspan="2"><bold>Cortex</bold></td>
<td align="left" valign="top">rTBI</td>
<td align="left" valign="top">1 ±0.14</td>
<td align="left" valign="top"><italic>0.6399</italic></td>
<td align="left" valign="top">0.72 ±0.35</td>
<td align="left" valign="top"><italic>0.1502</italic></td>
</tr>
<tr>
<td align="left" valign="top">Sham</td>
<td align="left" valign="top">1 ±0.07</td>
<td align="left" valign="top"/>
<td align="left" valign="top">1 ±0.33</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" rowspan="2"><bold>Hippocampus</bold></td>
<td align="left" valign="top">rTBI</td>
<td align="left" valign="top">0.91 ±0.31</td>
<td align="left" valign="top"><italic>0.5090</italic></td>
<td align="left" valign="top">1 ±0.77</td>
<td align="left" valign="top"><italic>0.9147</italic></td>
</tr>
<tr>
<td align="left" valign="top">Sham</td>
<td align="left" valign="top">1 ±0.17</td>
<td align="left" valign="top"/>
<td align="left" valign="top">1 ±0.58</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" rowspan="2"><bold>Thalamus</bold></td>
<td align="left" valign="top">rTBI</td>
<td align="left" valign="top">0.89 ±0.34</td>
<td align="left" valign="top"><italic>0.4891</italic></td>
<td align="left" valign="top">0.75 ±0.59</td>
<td align="left" valign="top"><italic>0.3361</italic></td>
</tr>
<tr>
<td align="left" valign="top">Sham</td>
<td align="left" valign="top">1 ± 0.24</td>
<td align="left" valign="top"/>
<td align="left" valign="top">1 ±0.27</td>
<td align="left" valign="top"/>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="tfn4"><p>Unpaired t-test.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Altogether, our results indicate that PDH activity is decreased in the cortical areas following rTBI, while LDH activity, MCT1 and MCT4 expression are not significantly different compared to Sham at 3.5 months post-injury.</p>
</sec>
<sec id="s2-4">
<title>Machine learning identifies rTBI/Sham classifiers, and predictors of behavior and HP <sup>13</sup>C readouts</title>
<p>The machine learning (ML) analysis included all the data described above, as well as behavioral data we previously reported in Krukowski <italic>et al</italic>.<sup><xref ref-type="bibr" rid="c35">35</xref></sup>, which showed that mild rTBI leads to increased risk-taking behavior in male mice at 100 days post-injury.</p>
<p>Given n = 20 (10 for rTBI and 10 for Sham) mice along with 44 measured variables (see <xref ref-type="table" rid="tbl3">Table 3</xref> for list of variables and abbreviations), we used ML to perform two types of analyses. First, we wanted to identify the best classifying variables allowing for separation of the two groups (rTBI vs Sham). Second, we aimed to find the best predictors of changes in risk-taking behavior, as it recapitulates a key behavioral component observed in rTBI patients, and of cortical HP <sup>13</sup>C Lac/Pyr, due to its potential to serve as a novel biomarker for long-lasting consequences of rTBI.</p>
<table-wrap id="tbl3" position="float" orientation="portrait">
<label>Table 3</label>
<caption><title>List of variables used for ML analyses.</title></caption>
<alternatives>
<graphic xlink:href="3166656v1_tbl3.tif" mime-subtype="tif" mimetype="image"/>
<graphic xlink:href="3166656v1_tbl4.tif" mime-subtype="tif" mimetype="image"/>
<table frame="box" rules="rows">
<thead>
<tr>
<th align="left" valign="top">Variable abbreviation</th>
<th align="left" valign="top">Variable description</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">EPM frequency extreme</td>
<td align="left" valign="top">Number of entries into the extreme zones on the EPM</td>
</tr>
<tr>
<td align="left" valign="top">EPM duration extreme</td>
<td align="left" valign="top">Time (sec) in the extreme zones on the EPM</td>
</tr>
<tr>
<td align="left" valign="top">EPM frequency openandcenter</td>
<td align="left" valign="top">Number of entries in the Open + Center on EPM</td>
</tr>
<tr>
<td align="left" valign="top">EPM duration openandcenter</td>
<td align="left" valign="top">Time (sec) in the open + Center on the EPM</td>
</tr>
<tr>
<td align="left" valign="top">EPM totaldistance centerpoint</td>
<td align="left" valign="top">Total distance traveled on EPM, measured by centerpoint, units = cm</td>
</tr>
<tr>
<td align="left" valign="top">EPM averagevelocity centerpoint</td>
<td align="left" valign="top">Average animal velocity on the EPM, units = cm/sec</td>
</tr>
<tr>
<td align="left" valign="top">HP <sup>13</sup>C Urea Ctx</td>
<td align="left" valign="top">Hyperpolarized [<sup>13</sup>C]urea level in cortical area</td>
</tr>
<tr>
<td align="left" valign="top">HP <sup>13</sup>C Lac/Pyr Ctx</td>
<td align="left" valign="top">Hyperpolarized lactate/pyruvate ratio in cortical area</td>
</tr>
<tr>
<td align="left" valign="top">HP <sup>13</sup>C Urea Subctx</td>
<td align="left" valign="top">Hyperpolarized [<sup>13</sup>C]urea level in subcortical area</td>
</tr>
<tr>
<td align="left" valign="top">HP <sup>13</sup>C Lac/Pyr Subctx</td>
<td align="left" valign="top">Hyperpolarized lactate/pyruvate ratio in subcortical area</td>
</tr>
<tr>
<td align="left" valign="top">PDH Pfc</td>
<td align="left" valign="top">PDH activity in prefrontal cortex</td>
</tr>
<tr>
<td align="left" valign="top">PDH Ctx</td>
<td align="left" valign="top">PDH activity in cortex</td>
</tr>
<tr>
<td align="left" valign="top">PDH Hp</td>
<td align="left" valign="top">PDH activity in hippocampus</td>
</tr>
<tr>
<td align="left" valign="top">PDH Thal</td>
<td align="left" valign="top">PDH activity in thalamus</td>
</tr>
<tr>
<td align="left" valign="top">nT<sub>2</sub> Ctx</td>
<td align="left" valign="top">Normalized T<sub>2</sub> intensity value in cortex</td>
</tr>
<tr>
<td align="left" valign="top">nT<sub>2</sub> Hp</td>
<td align="left" valign="top">Normalized T<sub>2</sub> intensity value in hippocampus</td>
</tr>
<tr>
<td align="left" valign="top">nT<sub>2</sub> Pfc</td>
<td align="left" valign="top">Normalized T<sub>2</sub> intensity value in prefrontal cortex</td>
</tr>
<tr>
<td align="left" valign="top">nT<sub>2</sub> Subctx</td>
<td align="left" valign="top">Normalized T<sub>2</sub> intensity value in subcortical areas</td>
</tr>
<tr>
<td align="left" valign="top">Volume Ctx</td>
<td align="left" valign="top">Volume of cortex calculted from T<sub>2</sub>w MRI</td>
</tr>
<tr>
<td align="left" valign="top">Volume Hp</td>
<td align="left" valign="top">Volume of hippocampus calculated from T<sub>2</sub>w MRI</td>
</tr>
<tr>
<td align="left" valign="top">Volume Pfc</td>
<td align="left" valign="top">Volume of prefrontal cortex calculated from T<sub>2</sub>w MRI</td>
</tr>
<tr>
<td align="left" valign="top">Volume Subctx</td>
<td align="left" valign="top">Volume of subcortical areas calculated from T<sub>2</sub>w MRI</td>
</tr>
<tr>
<td align="left" valign="top">Volume Ventricle</td>
<td align="left" valign="top">Volume of ventricles calculated from T<sub>2</sub>w MRI</td>
</tr>
<tr>
<td align="left" valign="top">Volume Brain</td>
<td align="left" valign="top">Volume of whole brain calculated from T<sub>2</sub>w MRI</td>
</tr>
<tr>
<td align="left" valign="top">T<sub>1</sub> Ctx</td>
<td align="left" valign="top">T<sub>1</sub> value in cortex</td>
</tr>
<tr>
<td align="left" valign="top">T<sub>1</sub> Hp</td>
<td align="left" valign="top">T<sub>1</sub> value in hippcampus</td>
</tr>
<tr>
<td align="left" valign="top">T<sub>1</sub> Pfc</td>
<td align="left" valign="top">T<sub>1</sub> value in prefrontal cortex</td>
</tr>
<tr>
<td align="left" valign="top">T<sub>1</sub> Subctx</td>
<td align="left" valign="top">T<sub>1</sub> value in subcortex</td>
</tr>
<tr>
<td align="left" valign="top">MCT1 Thal</td>
<td align="left" valign="top">MCT1 expression in thalamus</td>
</tr>
<tr>
<td align="left" valign="top">MCT1 Hp</td>
<td align="left" valign="top">MCT1 expression in hippocampus</td>
</tr>
<tr>
<td align="left" valign="top">MCT1 Ctx</td>
<td align="left" valign="top">MCT1 expression in cortex</td>
</tr>
<tr>
<td align="left" valign="top">MCT1 Pfc</td>
<td align="left" valign="top">MCT1 expression in prefrontal cortex</td>
</tr>
<tr>
<td align="left" valign="top">MCT4 Thal</td>
<td align="left" valign="top">MCT4 expression in thalamus</td>
</tr>
<tr>
<td align="left" valign="top">MCT4 Hp</td>
<td align="left" valign="top">MCT4 expression in hippocampus</td>
</tr>
<tr>
<td align="left" valign="top">MCT4 Ctx</td>
<td align="left" valign="top">MCT4 expression in cortex</td>
</tr>
<tr>
<td align="left" valign="top">MCT4 Pfc</td>
<td align="left" valign="top">MCT4 expression in prefrontal cortex</td>
</tr>
<tr>
<td align="left" valign="top">LDH Thal</td>
<td align="left" valign="top">LDH activity in thalamus</td>
</tr>
<tr>
<td align="left" valign="top">LDH Hp</td>
<td align="left" valign="top">LDH activity in hippocampus</td>
</tr>
<tr>
<td align="left" valign="top">LDH Ctx</td>
<td align="left" valign="top">LDH activity in cortex</td>
</tr>
<tr>
<td align="left" valign="top">LDH Pfc</td>
<td align="left" valign="top">LDH activity in prefrontal cortex</td>
</tr>
<tr>
<td align="left" valign="top">SWI Ctx</td>
<td align="left" valign="top">SWI value in cortex</td>
</tr>
<tr>
<td align="left" valign="top">SWI Hp</td>
<td align="left" valign="top">SWI value in hippcampus</td>
</tr>
<tr>
<td align="left" valign="top">SWI Pfc</td>
<td align="left" valign="top">SWI value in prefrontal cortex</td>
</tr>
<tr>
<td align="left" valign="top">SWI Subctx</td>
<td align="left" valign="top">SWI value in subcortex</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<p>Various classification and feature extraction methods were implemented to identify the best classifying variables between Sham and rTBI mice. Consequently, we identified five triplets of variables that could accurately distinguish between either group and ranked them based on their feature importance scores computed using various feature extraction algorithms (see methods). The top two triplets with high feature scores are presented in <xref ref-type="fig" rid="fig5">Fig. 5.<bold>a</bold></xref> and the others are shown in <xref ref-type="fig" rid="fig7">Supplementary Fig. 2</xref>. The top two triplets are: 1) PDH Pfc, LDH Thal, and LDH Hp, and 2) PDH Ctx, LDH Thal, and HP <sup>13</sup>C Lac/Pyr Ctx. These findings suggest that although one single feature is not sufficient to identify the difference between rTBI and Sham, the combined PDH and LDH activity, as well as HP <sup>13</sup>C imaging readouts can help distinguish differences between the two conditions. The three lower-tier triplets consisted of the subsequent variables: 3) PDH Pfc, EPM duration openandcenter, and LDH Thal, 4) PDH Pfc, EPM duration openandcenter, and HP <sup>13</sup>C Lac/Pyr Ctx, and 5) PDH Pfc, MCT1 Pfc, and HP <sup>13</sup>C Lac/Pyr Ctx. These three last triplets further idenfy the risk-taking behavior and MCT1 expression in the prefrontal cortex as important variables to classify Sham and rTBI.</p>
<fig id="fig5" position="float" fig-type="figure">
<label>Figure 5</label>
<caption><title>ML analyses identify best rTBI and Sham classifiers and best predictors of changes in risk-taking behavior and HP <sup>13</sup>C Lac/Pyr Ctx.</title>
<p><bold>(a)</bold> Top two triplets that can classify rTBI (red) and Sham (black) mice. Here, circles represent the mice for which all three variables are measured whereas triangles represent mice for which at least one of the three variables were missing and predicted by ML algorithms (see Methods). <bold>(b-c)</bold> Prediction performance of the best predictors of risk-taking behavior (<bold>b</bold>, bottom panel), and HP <sup>13</sup>C Lac/Pyr Ctx (<bold>c</bold>, bottom panel) compared to the prediction performance of the case in which all variables are used (<bold>b-c</bold> top panel). <italic>N</italic>= 10 rTBI and 10 Sham mice.</p></caption>
<graphic xlink:href="3166656v1_fig5.tif" mime-subtype="tif" mimetype="image"/>
</fig>
<p>Next, we identified the best predictors of the changes in risk-taking behavior and HP <sup>13</sup>C Lac/Pyr Ctx presented in <xref ref-type="fig" rid="fig5">Fig. 5.<bold>b and 5.c</bold></xref>, respectively. Interestingly, four variables, namely EPM frequency openandcenter, MCT1 Pfc, nT<sub>2</sub> Pfc, and HP <sup>13</sup>C Lac/Pyr Ctx, were sufficient to predict risk-taking behavior (<xref ref-type="fig" rid="fig5">Fig. 5.<bold>b bottom panel</bold></xref>) with similar accuracy than when all variables were used for prediction (<xref ref-type="fig" rid="fig5">Fig. 5.<bold>b top panel</bold></xref>). This result shows that a systems approach comprising behavioral, transporter expression, structural and HP <sup>13</sup>C imaging measures yields a tangible prediction for changes in risk-taking behavior. Similarly, four variables, namely EPM duration openandcenter, HP <sup>13</sup>C Lac/Pyr Subctx, PDH Hp, and SWI Hp, were enough to predict the HP <sup>13</sup>C Lac/Pyr Ctx (<xref ref-type="fig" rid="fig5">Fig. 5.<bold>c bottom panel</bold></xref>) with similar accuracy than when all the variables were used for prediction (<xref ref-type="fig" rid="fig5">Fig. 5.<bold>c top panel</bold></xref>). This result demonstrates that using a systemic combination of behavioral, enzyme activity, and advanced MRI measures best predicts the HP <sup>13</sup>C Lac/Pyr Ctx.</p>
</sec>
</sec>
<sec id="s3" sec-type="discussion">
<title>Discussion</title>
<p>In this study, we demonstrated that HP <sup>13</sup>C MRSI of [1-<sup>13</sup>C]pyruvate can detect metabolic changes 3.5 months following rTBI when structural T<sub>2</sub> MRI, T<sub>1</sub> mapping, SWI MRI and HP <sup>13</sup>C MRSI of [<sup>13</sup>C]urea did not. Specifically, we measured a significantly lower HP <sup>13</sup>C Lac/Pyr in the mouse cortex 3.5 months postinjury, which was associated with lower PDH activity. Using a ML approach, we further validated that the HP <sup>13</sup>C Lac/Pyr is among the best classifiers of rTBI and Sham groups, and is a predictor of the risktaking behavior observed in this rTBI model. Our findings demonstrate the ability of HP <sup>13</sup>C MRSI of [1-<sup>13</sup>C]pyruvate to detect rTBI-induced damages and highlight promising potential to improve diagnosis and monitoring of rTBI patients at chronic time points when other imaging techniques are insufficient.</p>
<p>Cerebral metabolism has been probed using HP [1-<sup>13</sup>C]pyruvate both in preclinical and clinical settings in healthy and diseased brain (see Le Page &amp; al. for recent literature review<sup><xref ref-type="bibr" rid="c21">21</xref></sup>). Prior studies performed in moderate TBI preclinical models of contusion injury have reported increased HP <sup>13</sup>C Lac/Pyr at early timepoints following injury (4 hours up to 7 days following injury), but no significant changes at chronic timepoints (28 days post-injury)<sup><xref ref-type="bibr" rid="c24">24</xref>, <xref ref-type="bibr" rid="c25">25</xref></sup>. In contrast, in this study we observed a decreased HP <sup>13</sup>C Lac/Pyr at chronic timepoints, suggesting different underlying pathological changes between contusion injury and rTBI. Studies performed using positron emission tomography (PET) imaging with the glucose analogue <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) have detected long-term brain hypometabolism following TBI<sup><xref ref-type="bibr" rid="c4">4</xref>, <xref ref-type="bibr" rid="c5">5</xref>, <xref ref-type="bibr" rid="c36">36</xref></sup>, which is in line with the lower HP <sup>13</sup>C Lac/Pyr measured here at chronic timepoints. To the best of our knowledge, <sup>18</sup>F-FDG PET imaging has never been applied to CHIMERA rTBI model. Furthermore, the use of this method for TBI is limited by ionizing radiations, and the high background of <sup>18</sup>F-FDG PET signal in the brain tissue, hampering the detection of small changes in glucose uptake.</p>
<p>Decreased HP <sup>13</sup>C bicarbonate / lactate ratio was found in moderate TBI models<sup><xref ref-type="bibr" rid="c25">25</xref></sup>, and decreased HP <sup>13</sup>C bicarbonate levels were found in TBI patients<sup><xref ref-type="bibr" rid="c26">26</xref></sup>, highlighting possible changes in mitochondrial function and aerobic versus anaerobic respiration following trauma. In agreement with these findings, a decreased of PDH activity after injury has been previously described<sup><xref ref-type="bibr" rid="c24">24</xref>, <xref ref-type="bibr" rid="c37">37</xref></sup>, including in our current findings in rTBI. In this study, we were not able to detect 13C bicarbonate, likely due to the low signal to noise and the fast T<sub>1</sub> relaxation rate of this metabolite at ultra-high field (14.1 Tesla). HP <sup>13</sup>C Lac/Pyr can be influenced by the activity of LDH and/or PDH, the availability of their cofactors<sup><xref ref-type="bibr" rid="c38">38</xref>, <xref ref-type="bibr" rid="c39">39</xref>, <xref ref-type="bibr" rid="c40">40</xref></sup>, as well as by MCTs expression, where increased MCT1 expression leads to increased HP <sup>13</sup>C Lac/Pyr in selected cell lines<sup><xref ref-type="bibr" rid="c41">41</xref></sup>. In this study, we did not find any significant differences in MCT1 and MCT4 between rTBI and Sham mice, suggesting that they do not play a prominent role in the changes observed in the HP <sup>13</sup>C Lac/Pyr at this late time post injury.</p>
<p>It has previously been shown that the blood-brain-barrier (BBB) limits the entry of HP probes, which could in turn influence the measured HP <sup>13</sup>C Lac/Pyr<sup><xref ref-type="bibr" rid="c42">42</xref>, <xref ref-type="bibr" rid="c43">43</xref></sup>. To evaluate potential changes in perfusion and delivery, we co-injected [1-<sup>13</sup>C]pyruvate with HP [<sup>13</sup>C]urea, a metabolically inactive probe. Although decreased cerebral blood flow alteration has been reported following rTBI<sup><xref ref-type="bibr" rid="c44">44</xref>, <xref ref-type="bibr" rid="c45">45</xref></sup>, we did not observe any differences in HP [<sup>13</sup>C]urea levels between Sham and rTBI, indicating that perfusion was likely unaltered at 3.5 months post-injury. To the best of our knowledge, this is the first study reporting the use of HP [<sup>13</sup>C]urea in a rTBI model. Additional studies at earlier timepoints following injury, and in other TBI models, are needed to evaluate the full potential of HP [<sup>13</sup>C]urea in detecting BBB alterations and/or vasculature changes following brain injury.</p>
<p>Conventional and advanced anatomical MRI did not detect any differences between Sham and rTBI at 3.5 months post-injury. In agreement with these findings, Haber <italic>et al.</italic> and our group previously reported no differences using T<sub>2</sub> MRI at 7 days and 40 days post-injury, respectively<sup><xref ref-type="bibr" rid="c10">10</xref>, <xref ref-type="bibr" rid="c12">12</xref></sup>. These results suggest that conventional T<sub>2</sub> MRI may not be able to detect rTBI patholology-induced using the CHIMERA device, either at early or late timepoints following injury. Using T<sub>1</sub> mapping we investigated whether we could detect changes in tissue microstructure and reactive oxygen species production, but found no differences between Sham and rTBI<sup><xref ref-type="bibr" rid="c34">34</xref></sup>. Oxidative stress and reactive oxygen species have been shown to play an important role in TBI pathogenesis and in mediating axonal degeneration<sup><xref ref-type="bibr" rid="c46">46</xref>, <xref ref-type="bibr" rid="c47">47</xref>, <xref ref-type="bibr" rid="c48">48</xref></sup>. However it remains unclear if these events may predominantly occur at early timepoints following injury and would have resolved by the time we performed our imaging study (3.5 months injury), or whether T<sub>1</sub> mapping was not able to detect these events in this rTBI model. HP [1-<sup>13</sup>C]dehydroascorbic acid (DHA) and HP [1-<sup>13</sup>C]N-acetyl cysteine (NAC) have been shown to be sensitive probes to investigate redox changes <italic>in vivc/</italic><sup><xref ref-type="bibr" rid="c49">49</xref>, <xref ref-type="bibr" rid="c50">50</xref></sup>, and therefore represent attractive probes to further interrogate the involvement of oxidative stress using HP <sup>13</sup>C MRSI. We also included SWI MRI exams as this method has been shown to improve the detection of microbleeds and hemorrhagic diffusive axonal injury after TBI, which was associated with neurologic deficits and long-term outcome in human TBI<sup><xref ref-type="bibr" rid="c51">51</xref>, <xref ref-type="bibr" rid="c52">52</xref></sup>. However, we did not detect any differences in SWI MRI between Sham and rTBI. As for T<sub>1</sub> mapping, it remains to be determined whether no microbleeds or oxygenation changes occurs in this model at early timepoints, or whether potential changes have resolved by the time we conducted our imaging exams.</p>
<p>We took a systems approach to measure behavior outcomes using ML analyses. We found that sets of variables were able to classify rTBI and Sham mice. These variables are linked to cognitive abilities (risktaking behavior), metabolism and molecule transport (PDH and LDH activity, HP <sup>13</sup>C Lac/Pyr, and MCT1), highlighting the importance of long-term metabolic impairment in rTBI and suggesting their potential as injury biomarkers. Interestingly, ML was able to identify that enzymatic changes in the thalamus and hippocampus regions, which were not statistically significant using conventional unpaired t-test in isolation, became important variables to classify rTBI and Sham when considered together. This is in agreement with changes in hippocampal function that have been previously reported in rTBI up to 6 months post-injury<sup><xref ref-type="bibr" rid="c53">53</xref></sup>. Future HP <sup>13</sup>C imaging studies will aim to also include the thalamus and hippocampus to determine whether <italic>in vivo</italic> metabolic changes can be detected in these regions. ML was also used to determine which variables are best predictors of the risk-taking behavior. We found that the changes in risk-taking behavior were best predicted by variables from the cortical areas, including HP <sup>13</sup>C Lac/Pyr, MCT1 expression, structural MRI, and behavioral parameters. Similarly, cerebral microdialysis studies have shown that the Lac/Pyr is an important variable associated to clinical outcome. High Lac/Pyr within the first days after injury was associated to poor clinical outcome 6 months later<sup><xref ref-type="bibr" rid="c18">18</xref></sup>, while here we show that a lower HP <sup>13</sup>C Lac/Pyr is associated to higher risk-taking behavior 3.5 months after injury. This discrepancy might be explained by different timing of the Lac/Pyr measurement (days versus months after injury), and the injury severity (severe TBI versus mild rTBI). Nonetheless, our study provides further evidence that the Lac/Pyr is a useful marker to predict behavioral outcome, which can now be measured in a non-invasive manner using HP <sup>13</sup>C MRSI, thus opening new avenues to evaluate metabolic alterations months after trauma. Last, ML was used to determine the best predictors of the HP <sup>13</sup>C Lac/Pyr in the cortex, and identified subcortical variables, including PDH activity, SWI MRI and metabolic MRSI, as well as risk-taking behavior. Altogether, these results demonstrate the importance of multimodal approaches to detect rTBI pathology and associated long-lasting changes.</p>
<p>Thanks to the recent efforts of the community to enable easy data sharing though data repository<sup><xref ref-type="bibr" rid="c54">54</xref></sup>, future studies with higher sample size will become possible, which in turn can lead to improvement of our understanding of biological and functional pathway involved in rTBI, and help identify novel biomarkers.</p>
<p>In summary, our findings demonstrate the potential of HP [1-<sup>13</sup>C]pyruvate to detect long-lasting metabolic alterations in a mouse model of rTBI. In addition, ML identified HP <sup>13</sup>C MRSI as a key parameter to predict long-term rTBI-induced behavioral outcomes. Over the past few years, the use of HP <sup>13</sup>C MRSI in clinical trials worldwide has been rapidly expanding, and the injection of HP [1-<sup>13</sup>C]pyruvate has proven feasible and safe, with no reported side effects<sup><xref ref-type="bibr" rid="c55">55</xref></sup>. In this study, we were able to measure changes in HP <sup>13</sup>C MRS parameters from two regions, the cortex which is closest to the impact, and the subcortex, which is more remote. We were not able to differentiate between smaller brain regions (e.g. prefrontal cortex, hippocampus, thalamus) due to the large voxel size used in this study relative to the size of the mouse brain. Current sequences available on clinical scanners can achieve up to 1 cm<sup>3</sup> spatial resolution and cover the entire human brain, thus providing metabolic information from brain areas close and remote to the site of injury. With the growing availability of the HP <sup>13</sup>C MRS technology, our findings provide a strong rationale to translate its use in patients suffering from rTBI, with the aim to improve the detection of rTBI-induced damages, help in understanding metabolic pathways involved in rTBI pathogenesis, and eventually aid the development of treatment strategies.</p>
</sec>
<sec id="s4" sec-type="methods">
<title>Methods</title>
<sec id="s4-1">
<title>Animals and rTBI model induction</title>
<p>All animal research was approved by the Institutional Animal Care and Use Committee of the University of California, San Francisco. Mice were given one week of acclimation and housed with a reversed 12-h light/12-h dark cycle and provided food and water ad libitum. At 8 weeks of age, mice were randomly assigned to the rTBI or sham control group. Animals were anesthetized using isoflurane (2-3%) in oxygen 1 L/min during the procedure. rTBI animals were subjected to multiple, mild, closed-head injuries using the CHIMERA device as previously reported<sup><xref ref-type="bibr" rid="c10">10</xref>, <xref ref-type="bibr" rid="c35">35</xref></sup>. Briefly, rTBI animals were placed supinely into an angled holding platform without any shaving of the head or incision into the skin so that the head was level with the piston target hole while aligning the eyes, ears, and nose such that the impact was centered on the dorsal convexity of the skull, targeting a 5-mm area surrounding bregma. A nose cone delivering isoflurane was removed just prior to the impact. Impact was initiated using RealTerm software, which was connected to a system including air tank, pressure regulator, digital pressure gauge, two-way solenoid valve, and piston. The impact was administered with a velocity range of 3.9-4.5 m/sec, resulting in an impact energy of 0.5 J from the 5 mm, 50 g piston<sup><xref ref-type="bibr" rid="c10">10</xref>, <xref ref-type="bibr" rid="c35">35</xref></sup>. Animals were moved to an incubator immediately after the impact and monitored until fully recovered. rTBI animals received an injury once per day for 5 days with a 24 h interval in between impacts. Five repeated hits were chosen to specifically focus on the effects of repeated exposure to TBI, as athletes, veterans and sometimes trauma victims are exposed to constant and repeated blows, even without experiencing concussive symptoms. Sham mice were exposed to the same isoflurane anesthesia paradigm without sustaining an impact. Skull fractures, seizures, apnea, or mortality were not observed in any animals, and no animals were excluded from the study due to injury parameters.</p>
</sec>
<sec id="s4-2">
<title>Risk-taking behavioral test</title>
<p>For all behavioral assays, the experimenters were blinded to surgery. Before behavioral analysis, animals were inspected for gross motor impairments. Animals were inspected for whisker loss, limb immobility (including grip strength), and eye occlusions. If animals displayed any of these impairments, they were eliminated from the study. Behavioral tests were recorded and scored using a video tracking and analysis setup (Ethovision XT 8.5, Noldus Information Technology). If tracking was unsuccessful, videos were scored by two individuals blinded to surgery. Risk-taking behavioral phenotype was evaluated using the Elevated Plus Maze (EPM) at ~ 100 days (3 months) post-injury (counted from the day of the first injury) as described previously<sup><xref ref-type="bibr" rid="c10">10</xref>, <xref ref-type="bibr" rid="c35">35</xref></sup>. The EPM consists of two exposed, open arms (35 cm) opposite each other and two enclosed arms (30.5 cm) also across from each other. The four arms are attached to a center platform (4.5 cm square), and the entire maze is elevated 40 cm off the floor. Bright white lights illuminated both ends of the open arm. Mice were placed individually onto the center of the maze and allowed to explore the maze for 5 min, and their activity was recorded. The maze was cleaned with 70% ethanol between animals. Risk-taking behavior was measured by changes in time spent in the open arms + center of the EPM. We also measured the number of entries into the extremes zones on the EPM, the time spent in the extreme zons on the EPM, the number of entries in the open arms + center on the EPM, the total distance traveled on EPM measured by centerpoint, and the average animal velocity on the EPM. These behavioral data were previously reported in Krukowski <italic>et al</italic>.<sup><xref ref-type="bibr" rid="c35">35</xref></sup>.</p>
</sec>
<sec id="s4-3">
<title>Magnetic resonance imaging</title>
<p>Mice were anesthetized using isoflurane (1.5-2% in O<sub>2</sub>) and a 27-gauge catheter was placed in the tail vein to allow for intravenous (i.v.) injection. Next, animals were placed in a dedicated cylindrical cradle allowing for reproducible positioning of the mouse head; which was subsequently inserted inside a dual tune <sup>1</sup>H-<sup>13</sup>C volume coil (ØI = 40 mm) or a single tuned <sup>1</sup>H proton coil (ØI = 40 mm) in a 14.1 T vertical MR system (Agilent Technologies). Respiration rate was continuously monitored through the PC-sam software interface (SA Instrument, NY, USA).</p>
<p>First, T<sub>2</sub>-weighted images from the entire brain were acquired for adequate positioning of the grid used for hyperpolarized <sup>13</sup>C acquisitions using the following parameters: repetition time (TR) = 1200 ms, echo time (TE) = 20 ms, slice thickness 1.8 mm, 2 averages, matrix 256 × 256, field of view (FOV) 30 × 30 mm<sup>2</sup>. For HP <sup>13</sup>C MRSI acquisitions, 24 μL of [1-<sup>13</sup>C]pyruvate and 55 μL [<sup>13</sup>C]urea preparation were co-polarized using a Hypersense DNP polarizer (Oxford Instruments) for one hour. After dissolution, the HP [1-<sup>13</sup>C]pyruvate and [1-<sup>13</sup>C]urea preparation was rapidly dissolved in isotonic buffer (pH ~ 7) to a final concentration of 80 mM and 78 mM, respectively. A final volume of 300 ×L of the HP [1-<sup>13</sup>C]pyruvate and [<sup>13</sup>C]urea solution was then injected i.v. through the tail vein catheter. 2D dynamic chemical shift imaging <sup>13</sup>C data were acquired 16 seconds post i.v. injection of the HP [1-<sup>13</sup>C]pyruvate and [<sup>13</sup>C]urea solution using the following parameters: TR = 67 ms, TE = 0.58 ms, spectral width 5000 Hz, 256 points, flip angle 10°; matrix = 16 × 16, field of view (FOV) = 32 × 32 mm<sup>2</sup>; slice thickness 4 mm.</p>
<p>Next, for T<sub>2</sub>-weighted MRI, T<sub>1</sub> MRI and SWI acquistions, the dual tune <sup>1</sup>H-<sup>13</sup>C volume coil (ØI = 40 mm) was removed and replaced by a <sup>1</sup>H volume only coil (×I = 40 mm). T<sub>2</sub>-weighted MRI was acquired using a 2D fast spin-echo, with effective echo time (TE<sub>eff</sub>)/TR = 11.80/2006 ms, FOV = 25 × 25 mm<sup>2</sup>, in 256 × 256 array and 0.5 mm slice thickness. T<sub>1</sub>-mapping data were acquired using fast spin-echo with inversion recovery: TE<sub>eff</sub>/ TR = 7.44/10000 ms, 8 inversion times (TI): 100, 170, 310, 530, 940, 1640, 2900, 5000 ms, FOV = 30 × 30 mm<sup>2</sup>, in 128 × 128 array and 1 mm slice thickness. SWI acquisitions were acquired using TE<sub>eff</sub>/TR = 4.64/111.29 ms, FOV = 20 x 20 mm<sup>2</sup>, in a 256 × 256 array and 0.4 mm slice thickness.</p>
</sec>
<sec id="s4-4">
<title>Magnetic resonance imaging data analysis</title>
<p>Brain regions were manually delineated on T<sub>1</sub> maps, T<sub>2</sub>-weighted and SWI magnitude images for each mouse based on the Allen Adult Mouse Brain atlas (Allen Institute) using the Aedes region of interest package for MATLAB (Mathworks). For each region, brain volumes were calculated with the T<sub>2</sub>-weighted data, as well as the mean T<sub>2</sub>-weighted values which were normalized to the mean of the cerebrospinal fluid signal from the ventricles as signal value standard. The mean T<sub>1</sub> relaxation times was calculated from T<sub>1</sub> maps generated in VNMRj by pixel-wise fitting according to (<xref ref-type="disp-formula" rid="FD1">Eq. 1</xref>).</p>
<disp-formula id="FD1">
<alternatives>
<mml:math display="block" id="M1"><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>|</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>*</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mi>t</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo>|</mml:mo></mml:mrow></mml:math>
<graphic xlink:href="3166656v1_eqn1.tif" mime-subtype="tif" mimetype="image"/></alternatives>
<label>(eq. 1)</label>
</disp-formula>
<p>Where y is the measured signal from fast spin echo with multiple inversion recovery, and the three fit parameters: relaxation time T<sub>1</sub>, equilibrium longitudinal magnetization M<sub>0</sub>, and pre-inversion recovery longitudinal relaxation M(0). The TI list is used as input for time t.</p>
<p>SWI data were processed as previously described<sup><xref ref-type="bibr" rid="c32">32</xref></sup> with phase images unwrapped by PRELUDE (FSL), High pass Gaussian filtered with pixel size 32 × 32, and positive phase map scaling used (<xref ref-type="disp-formula" rid="FD2">Eq. 2</xref>).</p>
<disp-formula id="FD2">
<alternatives>
<mml:math display="block" id="M2"><mml:msub><mml:mi>φ</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mfrac><mml:mrow><mml:mrow><mml:mo>|</mml:mo><mml:mrow><mml:msub><mml:mi>φ</mml:mi><mml:mrow><mml:mi>max</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mi>φ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mrow><mml:mo>|</mml:mo><mml:mrow><mml:msub><mml:mi>φ</mml:mi><mml:mrow><mml:mi>max</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>|</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi>φ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>1</mml:mn></mml:mtd><mml:mtd><mml:mrow><mml:mi>φ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math>
<graphic xlink:href="3166656v1_eqn2.tif" mime-subtype="tif" mimetype="image"/></alternatives>
<label>(eq. 2)</label>
</disp-formula>
<p>Normalized positive phase map φ<sub>pos</sub>(t), where φ(t) is the filtered, unwrapped phase at location t, and φ<sub>max</sub> is the maximum phase of the slice of interest. The positive phase map is a spatial map varying between zero and one, with higher phase approaching zero and thus increasing contrast on the final merged SWI data. The phase map is multiplied with the magnitude image four times to create final SWI data<sup><xref ref-type="bibr" rid="c56">56</xref></sup>. The mean SWI intensity was calculated for each mouse for each brain region and normalized to the mean of the Sham for each region, which corresponds to 1.</p>
<p>HP <sup>13</sup>C MRS imaging data was analyzed using the in-house SIVIC software (<ext-link ext-link-type="uri" xlink:href="http://sourceforge.net/apps/trac/sivic/">http://sourceforge.net/apps/trac/sivic/</ext-link>) and custom-built programs written in MATLAB (MATLAB R2011 b, The MathWorks Inc.). The area under the curve (AUC) of HP [1-<sup>13</sup>C]pyruvate, AUC of HP [1-<sup>13</sup>C]lactate and AUC of HP [<sup>13</sup>C]urea were measured for each voxel and normalized to the noise level. To account for variations in polarization levels and delivery, HP [1-<sup>13</sup>C]pyruvate signal and HP [1-<sup>13</sup>C]lactate signal were calculated by dividing each value by the sum of HP [1-<sup>13</sup>C]pyruvate and HP [1-<sup>13</sup>C]lactate for each voxel. HP [<sup>13</sup>C]urea signal was obtained by normalizing HP [<sup>13</sup>C]urea signal from each brain voxel to the sum of [<sup>13</sup>C]urea signal from tissue surrounding the brain. HP <sup>13</sup>C Lac/Pyr was calculated as the ratio of the AUC. Next, average from voxels containing cortex or subcortex was calculated, and the obtained mean values were used to evaluate statistical significance between sham and rTBI groups. Color heatmaps of HP [1-<sup>13</sup>C]pyruvate, HP [1-<sup>13</sup>C]lactate, HP [<sup>13</sup>C]urea and HP <sup>13</sup>C Lac/Pyr were generated using a linear-based interpolation of the <sup>13</sup>C 2D CSI data to the resolution of the anatomical images using custom-built programs written in MATLAB and SIVIC.</p>
<sec id="s4-4-1">
<title>Ex vivo analyses of brain samples</title>
<p>Following the imaging session, mice were transcardially perfused with ice-cold phosphate buffered saline, and brains were rapidly dissected. Next, prefrontal cortex, cortex, thalamus and hippocampus were isolated and snap-frozen in liquid nitrogen. Samples were stored at −80°C until further processing for activity assays and western blots.</p>
<p>LDH and PDH activities were evaluated using spectrophotometric activity assay kits according to manufacturer’s guidelines (ab102526 and ab109902; Abcam, respectively), and normalized to protein concentration determined by the Bradford protein assay method.</p>
<p>For western blot analyses, frozen brain samples were then homogenized with RIPA buffer (Pierce, 89900) and protease inhibitor Halt™ Protease Inhibitor Cocktail (Thermo Scientific, 1862209) using a TissueLyser II (Qiagen). Lysate were incubated on ice for 15 minutes and then centrifuged at 14,000 rpm for 10 min at 4°C. Protein concentration in supernatants was determined using the Bradford protein assay method. Equal amount of proteins was loaded on Mini-Protean® TGX TM Precast gels 12% (BioRad, 456-1043) for 34 minutes at 200 V and 400 mA in Tris/Glycine/SDS Buffer, (BioRad, 1610732). Proteins were transferred onto 0.2 pm PVDF membranes (BioRad, 1704157) using Trans-Blot Turbo (BioRad) for 7 minutes using the following settings: 1.3 A, 25 V. Next, the membranes were blocked for 1 hour using Tris-buffered saline supplemented with 0.1% Tween 20% and 5% milk (Research Product International, M17200-500). Membranes were incubated with the primary antibodies: rabbit anti-MCT1/SLC16A1 pAb (Novus, NBP1-59656, lot C, 1:400), rabbit anti-MCT4 (Bethyl, A304-439A-M, 1:1000), rabbit mAb anti-beta-tubulin (9F3) (Cell Signaling, 2128S, 1:2000) diluted in Tris-buffered saline supplemented with 0.1% Tween 20% and 5% milk overnight. An anti-rabbit IgG HRP-linked secondary antibody (Cell Signaling, 7074S, 1:3000) was used to detect immune-reactive bands using enhanced chemiluminescence (ECL Western Blotting Substrate, Pierce, 32209) according to the manufacturer instructions. Quantification of protein bands was done by measuring band intensities using ImageJ software. MCT1 and MCT4 levels were normalized to beta-tubulin expression and expressed as the levels relative to the expression of Sham mice, which corresponds to 1.</p>
</sec>
</sec>
<sec id="s4-5">
<title>Machine Learning analyses</title>
<p>The ML pipeline is summarized in <xref ref-type="fig" rid="fig8">Supplementary Fig. 3</xref>. Preprocessing of the raw experimental data was performed before ML analyses to (i) scale the measurements for fair comparison and (ii) predict the</p>
<p>missing measurements. The raw measurements were rescaled using Scikit-learn python library’s standard scaler<sup><xref ref-type="bibr" rid="c57">57</xref></sup> (see <xref ref-type="fig" rid="fig9">Supplementary Fig. 4</xref> for an example of original versus scaled data distributions). For a few mice, we were not able to measure some of the variables due to tissue isolation (n = 2 rTBI and n = 2 Sham missing for PDH activity, n = 3-4 rTBI and n = 3 Sham missing for LDH activity, MCT1 and MCT4 expression) and low signal to noise of the HP [<sup>13</sup>C] imaging data (n = 1 rTBI mouse excluded). To impute the missing measurements we separated the data into rTBI and Sham groups, and within each group the data was split as training and testing. Mice with all measured variables were used to train a Random Forrest Regressor (RFR). The trained regressor was then used to predict missing measurements associated with the testing data.<sup><xref ref-type="bibr" rid="c58">58</xref></sup> To identify the variables that are the best classifiers of Sham and rTBI groups, and to eliminate sensitivity of the results to different methods, we used multiple Scikit-learn classifiers and feature selection algorithims that are neural network, logistic regression, recursive feature elimination (RFE), SelectKBest, feature importance with ExtraTreesClassifier, and LASSO. Using each method, all the variables were scored based on their importance in the classification of Sham versus rTBI and a pool of variables with high importance scores was created. From this pool, we created groups of best classifiers with the minimum number of variables, that is three in this case, and ranked those triplets of variables based on their individual importance scores across different methods. Similarly, to identify the best predictors of the risk-taking behavior and HP <sup>13</sup>C Lac/Pyr in the cortex, we trained multiple regression algorithms of Scikit-learn library that are LASSO, RFR, Ridge Regression, Support Vector Regressor, using the measurements of variable to be predicted as the y-values and all the remaining variables as the x-values (predictors). Then, the variables with high absolute coefficients were identified as the most important features that contribute to the prediction of the regressor. After pooling and grouping the variables with high feature scores across different algorithms, we observed the best predictor group with the minimum number of variables.</p>
</sec>
<sec id="s4-6">
<title>Statistical analysis</title>
<p>Results are expressed as mean ± standard deviation (SD). Statistical analyses of MRI, behavioral, and <italic>ex vivo</italic> parameters was performed using unpaired t-test (GraphPad Prism (v 9.1.2), (*p ≤ 0.05, **p ≤ 0.01, ***p≤ 0.001, ****p≤ 0.0001).</p>
</sec>
</sec>
</body>
<back>
<sec id="s6">
<title>Supplementary Information</title>
<fig id="fig6" position="float" fig-type="figure">
<label>Supplementary Figure 1.</label>
<caption><title>Brain region volumes.</title>
<p>Quantitative analyses of brain volumes calculated from T<sub>2</sub>-weighted MRI indicated no significant differences for the cortex, hippocampus, prefrontal cortex, thalamus, whole brain and ventricles areas between Sham (filled circles) and rTBI (red open circles). <italic>N=</italic> 10 rTBI and 10 Sham mice. Unpaired <italic>t</italic>-tests; data are expressed as means ± SD.</p></caption>
<graphic xlink:href="3166656v1_fig6.tif" mime-subtype="tif" mimetype="image"/>
</fig>
<fig id="fig7" position="float" fig-type="figure">
<label>Supplementary Figure 2.</label>
<caption><title>Other three best classifying triplets of rTBI and Sham mice.</title>
<p>Circles represent the mice for which all three variables are measured whereas triangles represent mice for which at least one of the three variables were missing and predicted by ML algorithms (see Methods). <italic>N=</italic> 10 rTBI and 10 Sham mice.</p></caption>
<graphic xlink:href="3166656v1_fig7.tif" mime-subtype="tif" mimetype="image"/>
</fig>
<fig id="fig8" position="float" fig-type="figure">
<label>Supplementary Figure 3.</label>
<caption><title>The ML pipeline.</title>
<p><bold>(1)</bold> The original data was scaled due to their numerical uneven scales for fair treatment within ML algorithms. <bold>(2)</bold> The scaled data was split into training and testing data separately for rTBI and Sham mice. <bold>(3)</bold> Random Forrest Regressor was trained using the training datasets and <bold>(4)</bold> missing variable measurements were predicted by the learned regressor using the testing data. <bold>(5)</bold> Lastly, ML classification and feature extraction algorithms were used to classify and rank the variables based on their contribution to the classification of the two groups. Each step is explained in details in the Methods section.</p></caption>
<graphic xlink:href="3166656v1_fig8.tif" mime-subtype="tif" mimetype="image"/>
</fig>
<fig id="fig9" position="float" fig-type="figure">
<label>Supplementary Figure 4.</label>
<caption><title>Example of original versus scaled data distributions.</title>
<p><bold>(a)</bold> Original measurements for Var 4. <bold>(b)</bold> Scaled measurements for Var 4. <italic>N=</italic> 10 rTBI and 10 Sham mice.</p></caption>
<graphic xlink:href="3166656v1_fig9.tif" mime-subtype="tif" mimetype="image"/>
</fig>
</sec>
<ack>
<title>Acknowledgements</title>
<p>This work was supported by research grants: NIH R01NS102156 (MC), NIH NIA grants R01AG056770 (SR) and NIH R21NS096718 (SR, MC), Dana Foundation: The David Mahoney Neuroimaging program (MC) and the NIH Hyperpolarized MRI Technology Resource Center P41EB013598. K.K. was supported by an NRSA post-doctoral fellowship from the NIA F32AG054126. AN was supported by the NINDS K08 NS114170.</p>
</ack>
<sec id="d1e2862" sec-type="additional-information">
<title>Additional information</title>
<sec id="s5">
<title>Author contributions</title>
<p>M.M.C., and S.R. designed research; C.G., K.Q., B.T., K.K., A.N., and M.S.P performed research; C.G., K.Q., B.T., K.K., A.N., M.O., and C.F.L. analyzed data; C.G. and M.M.C. wrote the paper.</p>
</sec>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brett</surname> <given-names>BL</given-names></string-name>, <string-name><surname>Gardner</surname> <given-names>RC</given-names></string-name>, <string-name><surname>Godbout</surname> <given-names>J</given-names></string-name>, <string-name><surname>Dams-O’Connor</surname> <given-names>K</given-names></string-name>, <string-name><surname>Keene</surname> <given-names>CD</given-names></string-name></person-group>. <article-title>Traumatic Brain Injury and Risk of Neurodegenerative Disorder</article-title>. <source>Biol Psychiatry</source> <volume>91</volume>, <fpage>498</fpage>–<lpage>507</lpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Ding</surname> <given-names>K</given-names></string-name>, <string-name><surname>Gupta</surname> <given-names>PK</given-names></string-name>, <string-name><surname>Diaz-Arrastia</surname> <given-names>R</given-names></string-name></person-group>. <chapter-title>Epilepsy after Traumatic Brain Injury</chapter-title>. In: <source>Translational Research in Traumatic Brain Injury</source> (<person-group person-group-type="editor"><string-name><surname>Laskowitz</surname> <given-names>D</given-names></string-name>, <string-name><surname>Grant</surname> <given-names>G</given-names></string-name></person-group>) (<year>2016</year>).</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hay</surname> <given-names>J</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>VE</given-names></string-name>, <string-name><surname>Smith</surname> <given-names>DH</given-names></string-name>, <string-name><surname>Stewart</surname> <given-names>W</given-names></string-name></person-group>. <article-title>Chronic Traumatic Encephalopathy: The Neuropathological Legacy of Traumatic Brain Injury</article-title>. <source>Annu Rev Pathol</source> <volume>11</volume>, <fpage>21</fpage>–<lpage>45</lpage> (<year>2016</year>).</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ng</surname> <given-names>TS</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Neuroimaging in repetitive brain trauma</article-title>. <source>Alzheimers Res Ther</source> <volume>6</volume>, <fpage>10</fpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Asken</surname> <given-names>BM</given-names></string-name>, <string-name><surname>Rabinovici</surname> <given-names>GD</given-names></string-name></person-group>. <article-title>Identifying degenerative effects of repetitive head trauma with neuroimaging: a clinically-oriented review</article-title>. <source>Acta Neuropathol Commun</source> <volume>9</volume>, <fpage>96</fpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Toth</surname> <given-names>A</given-names></string-name></person-group>. <chapter-title>Magnetic Resonance Imaging Application in the Area of Mild and Acute Traumatic Brain Injury: Implications for Diagnostic Markers?</chapter-title> In: <source>Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects</source> (<person-group person-group-type="editor"><string-name><surname>Kobeissy</surname> <given-names>FH</given-names></string-name></person-group>) (<year>2015</year>).</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McAteer</surname> <given-names>KM</given-names></string-name>, <string-name><surname>Turner</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Corrigan</surname> <given-names>F</given-names></string-name></person-group>. <article-title>Animal models of chronic traumatic encephalopathy</article-title>. <source>Concussion</source> <volume>2</volume>, <fpage>CNC32</fpage> (<year>2017</year>).</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoogenboom</surname> <given-names>WS</given-names></string-name>, <string-name><surname>Branch</surname> <given-names>CA</given-names></string-name>, <string-name><surname>Lipton</surname> <given-names>ML</given-names></string-name></person-group>. <article-title>Animal models of closed-skull, repetitive mild traumatic brain injury</article-title>. <source>Pharmacol Ther</source> <volume>198</volume>, <fpage>109</fpage>–<lpage>122</lpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Namjoshi</surname> <given-names>DR</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Merging pathology with biomechanics using CHIMERA (Closed-Head Impact Model of Engineered Rotational Acceleration): a novel, surgery-free model of traumatic brain injury</article-title>. <source>Mol Neurodegener</source> <volume>9</volume>, <fpage>55</fpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nolan</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Repeated Mild Head Injury Leads to Wide-Ranging Deficits in Higher-Order Cognitive Functions Associated with the Prefrontal Cortex</article-title>. <source>J Neurotrauma</source> <volume>35</volume>, <fpage>2425</fpage>–<lpage>2434</lpage> (<year>2018</year>).</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McNamara</surname> <given-names>EH</given-names></string-name>, <string-name><surname>Grillakis</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Tucker</surname> <given-names>LB</given-names></string-name>, <string-name><surname>McCabe</surname> <given-names>JT</given-names></string-name></person-group>. <article-title>The closed-head impact model of engineered rotational acceleration (CHIMERA) as an application for traumatic brain injury pre-clinical research: A status report</article-title>. <source>Exp Neurol</source> <volume>333</volume>, <fpage>113409</fpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Haber</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Defining an Analytic Framework to Evaluate Quantitative MRI Markers of Traumatic Axonal Injury: Preliminary Results in a Mouse Closed Head Injury Model</article-title>. <source>eNeuro</source> <volume>4</volume>, (<year>2017</year>).</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Komlosh</surname> <given-names>ME</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Using double pulsed-field gradient MRI to study tissue microstructure in traumatic brain injury (TBI)</article-title>. <source>Microporous Mesoporous Mater</source> <volume>269</volume>, <fpage>156</fpage>–<lpage>159</lpage> (<year>2018</year>).</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jalloh</surname> <given-names>I</given-names></string-name>, <string-name><surname>Carpenter</surname> <given-names>KL</given-names></string-name>, <string-name><surname>Helmy</surname> <given-names>A</given-names></string-name>, <string-name><surname>Carpenter</surname> <given-names>TA</given-names></string-name>, <string-name><surname>Menon</surname> <given-names>DK</given-names></string-name>, <string-name><surname>Hutchinson</surname> <given-names>PJ</given-names></string-name></person-group>. <article-title>Glucose metabolism following human traumatic brain injury: methods of assessment and pathophysiological findings</article-title>. <source>Metab Brain Dis</source> <volume>30</volume>, <fpage>615</fpage>–<lpage>632</lpage> (<year>2015</year>).</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Demers-Marcil</surname> <given-names>S</given-names></string-name>, <string-name><surname>Coles</surname> <given-names>JP</given-names></string-name></person-group> <article-title>Cerebral metabolic derangements following traumatic brain injury</article-title>. <source>Curr Opin Anaesthesiol</source> <volume>35</volume>, <fpage>562</fpage>–<lpage>569</lpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carpenter</surname> <given-names>KL</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>(13)C-labelled microdialysis studies of cerebral metabolism in TBI patients</article-title>. <source>Eur J Pharm Sci</source> <volume>57</volume>, <fpage>87</fpage>–<lpage>97</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guilfoyle</surname> <given-names>MR</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Characterising the dynamics of cerebral metabolic dysfunction following traumatic brain injury: A microdialysis study in 619 patients</article-title>. <source>PLoS One</source> <volume>16</volume>, <elocation-id>e0260291</elocation-id> (<year>2021</year>).</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Timofeev</surname> <given-names>I</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Cerebral extracellular chemistry and outcome following traumatic brain injury: a microdialysis study of 223 patients</article-title>. <source>Brain</source> <volume>134</volume>, <fpage>484</fpage>–<lpage>494</lpage> (<year>2011</year>).</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nelson</surname> <given-names>SJ</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Metabolic imaging of patients with prostate cancer using hyperpolarized [1-(1) (3)C]pyruvate</article-title>. <source>Sci TranslMed</source> <volume>5</volume>, <fpage>198ra108</fpage> (<year>2013</year>).</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname> <given-names>ZJ</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Hyperpolarized (13)C MRI: State of the Art and Future Directions</article-title>. <source>Radiology</source> <volume>291</volume>, <fpage>273</fpage>–<lpage>284</lpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Le Page</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Guglielmetti</surname> <given-names>C</given-names></string-name>, <string-name><surname>Taglang</surname> <given-names>C</given-names></string-name>, <string-name><surname>Chaumeil</surname> <given-names>MM</given-names></string-name></person-group>. <article-title>Imaging Brain Metabolism Using Hyperpolarized (13)C Magnetic Resonance Spectroscopy</article-title>. <source>Trends Neurosci</source> <volume>43</volume>, <fpage>343</fpage>–<lpage>354</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Vigneron</surname> <given-names>DB</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>D</given-names></string-name></person-group>. <article-title>Current human brain applications and challenges of dynamic hyperpolarized carbon-13 labeled pyruvate MR metabolic imaging</article-title>. <source>Eur J Nucl Med Mol Imaging</source> <volume>48</volume>, <fpage>4225</fpage>–<lpage>4235</lpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hurd</surname> <given-names>RE</given-names></string-name>, <string-name><surname>Yen</surname> <given-names>YF</given-names></string-name>, <string-name><surname>Tropp</surname> <given-names>J</given-names></string-name>, <string-name><surname>Pfefferbaum</surname> <given-names>A</given-names></string-name>, <string-name><surname>Spielman</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Mayer</surname> <given-names>D</given-names></string-name></person-group>. <article-title>Cerebral dynamics and metabolism of hyperpolarized [1-(13)C]pyruvate using time-resolved MR spectroscopic imaging</article-title>. <source>J Cereb Blood Flow Metab</source> <volume>30</volume>, <fpage>1734</fpage>–<lpage>1741</lpage> (<year>2010</year>).</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guglielmetti</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>In vivo metabolic imaging of Traumatic Brain Injury</article-title>. <source>Sci Rep</source> <volume>7</volume>, <fpage>17525</fpage> (<year>2017</year>).</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>DeVience</surname> <given-names>SJ</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Metabolic imaging of energy metabolism in traumatic brain injury using hyperpolarized [1-(13)C]pyruvate</article-title>. <source>Sci Rep</source> <volume>7</volume>, <fpage>1907</fpage> (<year>2017</year>).</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hackett</surname> <given-names>EP</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Imaging Acute Metabolic Changes in Patients with Mild Traumatic Brain Injury Using Hyperpolarized [1-(13)C]Pyruvate</article-title>. <source>iScience</source> <volume>23</volume>, <fpage>101885</fpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lau</surname> <given-names>AZ</given-names></string-name>, <string-name><surname>Miller</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Robson</surname> <given-names>MD</given-names></string-name>, <string-name><surname>Tyler</surname> <given-names>DJ</given-names></string-name></person-group>. <article-title>Simultaneous assessment of cardiac metabolism and perfusion using copolarized [1-(13) C]pyruvate and (13) C-urea</article-title>. <source>Magn Reson Med</source> <volume>77</volume>, <fpage>151</fpage>–<lpage>158</lpage> (<year>2017</year>).</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qin</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Simultaneous Metabolic and Perfusion Imaging Using Hyperpolarized (13)C MRI Can Evaluate Early and Dose-Dependent Response to Radiation Therapy in a Prostate Cancer Mouse Model</article-title>. <source>Int J Radiat Oncol Biol Phys</source> <volume>107</volume>, <fpage>887</fpage>–<lpage>896</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qin</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Clinical translation of hyperpolarized (13) C pyruvate and urea MRI for simultaneous metabolic and perfusion imaging</article-title>. <source>Magn Reson Med</source> <volume>87</volume>, <fpage>138</fpage>–<lpage>149</lpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>von Morze</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Investigating tumor perfusion and metabolism using multiple hyperpolarized (13)C compounds: HP001, pyruvate and urea</article-title>. <source>Magn Reson Imaging</source> <volume>30</volume>, <fpage>305</fpage>–<lpage>311</lpage> (<year>2012</year>).</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bok</surname> <given-names>R</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>The Role of Lactate Metabolism in Prostate Cancer Progression and Metastases Revealed by Dual-Agent Hyperpolarized (13)C MRSI</article-title>. <source>Cancers (Basel)</source> <volume>11</volume>, (<year>2019</year>).</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Haacke</surname> <given-names>EM</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>YC</given-names></string-name>, <string-name><surname>Reichenbach</surname> <given-names>JR</given-names></string-name></person-group>. <article-title>Susceptibility weighted imaging (SWI)</article-title>. <source>Magn Reson Med</source> <volume>52</volume>, <fpage>612</fpage>–<lpage>618</lpage> (<year>2004</year>).</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Haller</surname> <given-names>S</given-names></string-name>, <string-name><surname>Vernooij</surname> <given-names>MW</given-names></string-name>, <string-name><surname>Kuijer</surname> <given-names>JPA</given-names></string-name>, <string-name><surname>Larsson</surname> <given-names>EM</given-names></string-name>, <string-name><surname>Jager</surname> <given-names>HR</given-names></string-name>, <string-name><surname>Barkhof</surname> <given-names>F</given-names></string-name></person-group>. <article-title>Cerebral Microbleeds: Imaging and Clinical Significance</article-title>. <source>Radiology</source> <volume>287</volume>, <fpage>11</fpage>–<lpage>28</lpage> (<year>2018</year>).</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tain</surname> <given-names>RW</given-names></string-name>, <string-name><surname>Scotti</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Li</surname> <given-names>W</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>XJ</given-names></string-name>, <string-name><surname>Cai</surname> <given-names>K</given-names></string-name></person-group>. <article-title>Imaging short-lived reactive oxygen species (ROS) with endogenous contrast MRI</article-title>. <source>J Magn Reson Imaging</source> <volume>47</volume>, <fpage>222</fpage>–<lpage>229</lpage> (<year>2018</year>).</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Krukowski</surname> <given-names>K</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Integrated Stress Response Inhibitor Reverses Sex-Dependent Behavioral and CellSpecific Deficits after Mild Repetitive Head Trauma</article-title>. <source>J Neurotrauma</source> <volume>37</volume>, <fpage>1370</fpage>–<lpage>1380</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koerte</surname> <given-names>IK</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>A review of neuroimaging findings in repetitive brain trauma</article-title>. <source>Brain Pathol</source> <volume>25</volume>, <fpage>318349</fpage> (<year>2015</year>).</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sharma</surname> <given-names>P</given-names></string-name> <string-name><surname>Benford</surname> <given-names>B</given-names></string-name>, <string-name><surname>Li</surname> <given-names>ZZ</given-names></string-name>, <string-name><surname>Ling</surname> <given-names>GS</given-names></string-name></person-group>. <article-title>Role of pyruvate dehydrogenase complex in traumatic brain injury and Measurement of pyruvate dehydrogenase enzyme by dipstick test</article-title>. <source>JEmerg Trauma Shock</source> <volume>2</volume>, <fpage>67</fpage>–<lpage>72</lpage> (<year>2009</year>).</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brindle</surname> <given-names>KM</given-names></string-name></person-group>. <article-title>Imaging metabolism with hyperpolarized (13)C-labeled cell substrates</article-title>. <source>J Am Chem Soc</source> <volume>137</volume>, <fpage>6418</fpage>–<lpage>6427</lpage> (<year>2015</year>).</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Day</surname> <given-names>SE</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy</article-title>. <source>Nat Med</source> <volume>13</volume>, <fpage>1382</fpage>–<lpage>1387</lpage> (<year>2007</year>).</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Witney</surname> <given-names>TH</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized (13)C-labeled pyruvate utilization as methods for detecting tumor response to treatment</article-title>. <source>Neoplasia</source> <volume>11</volume>, <fpage>574</fpage>–<lpage>582</lpage>, (<year>2009</year>).</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rao</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Hyperpolarized [1-(13)C]pyruvate-to-[1-(13)C]lactate conversion is rate-limited by monocarboxylate transporter-1 in the plasma membrane</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>117</volume>, <fpage>22378</fpage>–<lpage>22389</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miller</surname> <given-names>JJ</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>(13)C Pyruvate Transport Across the Blood-Brain Barrier in Preclinical Hyperpolarised MRI</article-title>. <source>Sci Rep</source> <volume>8</volume>, <fpage>15082</fpage> (<year>2018</year>).</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hackett</surname> <given-names>EP</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Probing Cerebral Metabolism with Hyperpolarized (13)C Imaging after Opening the Blood-Brain Barrier with Focused Ultrasound</article-title>. <source>ACS Chem Neurosci</source> <volume>12</volume>, <fpage>2820</fpage>–<lpage>2828</lpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Clark</surname> <given-names>AL</given-names></string-name>, <string-name><surname>Weigand</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Bangen</surname> <given-names>KJ</given-names></string-name>, <string-name><surname>Merritt</surname> <given-names>VC</given-names></string-name>, <string-name><surname>Bondi</surname> <given-names>MW</given-names></string-name>, <string-name><surname>Delano-Wood</surname> <given-names>L</given-names></string-name></person-group>. <article-title>Repetitive mTBI is associated with age-related reductions in cerebral blood flow but not cortical thickness</article-title>. <source>J Cereb Blood Flow Metab</source> <volume>41</volume>, <fpage>431</fpage>–<lpage>444</lpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ojo</surname> <given-names>JO</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Chronic Repetitive Mild Traumatic Brain Injury Results in Reduced Cerebral Blood Flow, Axonal Injury, Gliosis, and Increased T-Tau and Tau Oligomers</article-title>. <source>J Neuropathol Exp Neurol</source> <volume>75</volume>, <fpage>636</fpage>–<lpage>655</lpage> (<year>2016</year>).</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Frati</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Diffuse Axonal Injury and Oxidative Stress: A Comprehensive Review</article-title>. <source>Int J Mol Sci</source> <volume>18</volume>, (<year>2017</year>).</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Delage</surname> <given-names>C</given-names></string-name>, <string-name><surname>Taib</surname> <given-names>T</given-names></string-name>, <string-name><surname>Mamma</surname> <given-names>C</given-names></string-name>, <string-name><surname>Lerouet</surname> <given-names>D</given-names></string-name>, <string-name><surname>Besson</surname> <given-names>VC</given-names></string-name></person-group>. <article-title>Traumatic Brain Injury: An Age-Dependent View of Post-Traumatic Neuroinflammation and Its Treatment</article-title>. <source>Pharmaceutics</source> <volume>13</volume>, (<year>2021</year>).</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ismail</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Traumatic Brain Injury: Oxidative Stress and Novel Anti-Oxidants Such as Mitoquinone and Edaravone</article-title>. <source>Antioxidants (Basel)</source> <volume>9</volume>, (<year>2020</year>).</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Keshari</surname> <given-names>KR</given-names></string-name>, <string-name><surname>Kurhanewicz</surname> <given-names>J</given-names></string-name>, <string-name><surname>Bok</surname> <given-names>R</given-names></string-name>, <string-name><surname>Larson</surname> <given-names>PE</given-names></string-name>, <string-name><surname>Vigneron</surname> <given-names>DB</given-names></string-name>, <string-name><surname>Wilson</surname> <given-names>DM</given-names></string-name></person-group>. <article-title>Hyperpolarized 13C dehydroascorbate as an endogenous redox sensor for in vivo metabolic imaging</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>108</volume>, <fpage>18606</fpage>–<lpage>18611</lpage> (<year>2011</year>).</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yamamoto</surname> <given-names>K</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Real-Time insight into in vivo redox status utilizing hyperpolarized [1-(13)C] N-acetyl cysteine</article-title>. <source>Sci Rep</source> <volume>11</volume>, <fpage>12155</fpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Park</surname> <given-names>SW</given-names></string-name>, <string-name><surname>Kang</surname> <given-names>SH</given-names></string-name>, <string-name><surname>Nam</surname> <given-names>TK</given-names></string-name>, <string-name><surname>Min</surname> <given-names>BK</given-names></string-name>, <string-name><surname>Hwang</surname> <given-names>SN</given-names></string-name></person-group>. <article-title>Detection of traumatic cerebral microbleeds by susceptibility-weighted image of MRI</article-title>. <source>J Korean Neurosurg Soc</source> <volume>46</volume>, <fpage>365</fpage>–<lpage>369</lpage> (<year>2009</year>).</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tong</surname> <given-names>KA</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Diffuse axonal injury in children: clinical correlation with hemorrhagic lesions</article-title>. <source>Ann Neurol</source> <volume>56</volume>, <fpage>36</fpage>–<lpage>50</lpage> (<year>2004</year>).</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname> <given-names>H</given-names></string-name>, <string-name><surname>Desai</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>HY</given-names></string-name></person-group>. <article-title>Repetitive Closed-Head Impact Model of Engineered Rotational Acceleration Induces Long-Term Cognitive Impairments with Persistent Astrogliosis and Microgliosis in Mice</article-title>. <source>J Neurotrauma</source> <volume>34</volume>, <fpage>2291</fpage>–<lpage>2302</lpage> (<year>2017</year>).</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chou</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Empowering Data Sharing and Analytics through the Open Data Commons for Traumatic Brain Injury Research</article-title>. <source>Neurotrauma Rep</source> <volume>3</volume>, <fpage>139</fpage>–<lpage>157</lpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vaeggemose</surname> <given-names>M</given-names></string-name>, <string-name><surname>R</surname> <given-names>FS</given-names></string-name>, <string-name><surname>Laustsen</surname> <given-names>C</given-names></string-name></person-group>. <article-title>Comprehensive Literature Review of Hyperpolarized Carbon-13 MRI: The Road to Clinical Application</article-title>. <source>Metabolites</source> <volume>11</volume>, (<year>2021</year>).</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Haacke</surname> <given-names>EM</given-names></string-name>, <string-name><surname>Mittal</surname> <given-names>S</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Neelavalli</surname> <given-names>J</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>YC</given-names></string-name></person-group>. <article-title>Susceptibility-weighted imaging: technical aspects and clinical applications, part 1</article-title>. <source>AJNR Am JNeuroradiol</source> <volume>30</volume>, <fpage>19</fpage>–<lpage>30</lpage> (<year>2009</year>).</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pedregosa</surname>. <given-names>F</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Scikit-learn: Machine Learning in Python</article-title>. <source>Journal of Machine Learning Research</source> <volume>12</volume>, <fpage>2825</fpage>–<lpage>2830</lpage> (<year>2011</year>).</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Emmanuel</surname> <given-names>T</given-names></string-name>, <string-name><surname>Maupong</surname> <given-names>T</given-names></string-name>, <string-name><surname>Mpoeleng</surname> <given-names>D</given-names></string-name>, <string-name><surname>Semong</surname> <given-names>T</given-names></string-name>, <string-name><surname>Mphago</surname> <given-names>B</given-names></string-name>, <string-name><surname>Tabona</surname> <given-names>O</given-names></string-name></person-group>. <article-title>A survey on missing data in machine learning</article-title>. <source>J Big Data</source> <volume>8</volume>, <fpage>140</fpage> (<year>2021</year>).</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.106736.1.sa1</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Jbabdi</surname>
<given-names>Saad</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>University of Oxford</institution>
</institution-wrap>
<city>Oxford</city>
<country>United Kingdom</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Incomplete</kwd>
<kwd>Solid</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Valuable</kwd>
</kwd-group>
</front-stub>
<body>
<p>This study presents a <bold>valuable</bold> finding on the perturbed pyruvate metabolism in models of repetitive traumatic brain injury. The evidence supporting the main claims of the authors is <bold>solid</bold>, but much of the accompanying analysis and interpretation relies on <bold>incomplete</bold> evidence. The work will be of interest to those working on the imaging of traumatic brain injury.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.106736.1.sa0</article-id>
<title-group>
<article-title>Joint Public Review:</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>The authors present a metabolic imaging study of pyruvate metabolism in a mouse model of repetitive traumatic brain injury in the chronic recovery stage. They measure pyruvate metabolism with hyperpolarised 13C magnetic resonance spectroscopic imaging. This is acquired alongside semi-quantitative MR imaging metrics, a behavioural measure, and postmortem measures of relevant enzyme activity and expression of metabolic transporter proteins. They find that the MRSI-measured cortical lactate/pyruvate ratio (and signal from pyruvate and lactate independently) can differentiate the rTBI group from the sham group. They additionally find that postmortem, cortical pyruvate dehydrogenase activity is a statistically significant discriminator. All other metrics (MRI and enzyme/transporter measures) are not significantly different between groups. Finally, using a machine learning approach, the authors investigate the predictive power of combinations of all measures.</p>
<p>Strengths:</p>
<p>The primary strength of this work is the likely robustness of the primary finding - that hyperpolarised 13C lactate/pyruvate metabolite ratios are perturbed in this chronic rTBI model compared to the sham control.</p>
<p>Weaknesses:</p>
<p>Focal alterations in blood-brain-barrier permeability may affect the primary lactate/pyruvate measures. Whilst 13C urea measures perfusion, urea remains purely extracellular; whilst in the metabolism of the healthy brain, pyruvate must be transported through two levels of monocarboxylate transporters (MCTs) - in the endothelium surrounding the capillary bed and then into the parenchyma. By mechanically disrupting the brain, tight junctions in the BBB may be disrupted, therefore increasing the flux of pyruvate across the BBB and increasing pyruvate availability. In this case, lac/pyr would be a poor measure of metabolism as &quot;delivery&quot; has changed. While the authors assess perfusion using HP urea, it is unclear whether or how this metric would change in the presence of BBB disruption in relatively large and well-vascularised voxels.</p>
<p>The finding that &quot;HP [1-13C]pyruvate levels were 1.05 fold higher&quot; indicates that delivery of pyruvate might be increased. It is unclear if normalisation to the combined amplitude of lactate and pyruvate is fair in the case that the volume fraction in the voxel might have increased. Ideally, the authors would estimate polarisation separately as a normalisation.</p>
<p>No estimate of uncertainty is provided for the primary metabolic measures. Note that the lactate-pyruvate ratio is not normally distributed (see doi: 10.1002/mrm.26615), and this should be accounted for when carrying out statistical tests.</p>
<p>All metabolic maps are shown masked to the brain and interpolated to the structural MRI resolution (around 20 times). Nor is there any characterisation of the spectroscopic imaging's voxel volume, including the effect of the point spread function. It is, therefore, hard to have confidence in any spatial effects or potential partial volume effects from the tissue surrounding the brain.</p>
<p>The t2-weighted and SWI MRI measures used in this work are not quantitative. Normalisation in each case is carried out without regard to any spatially variable transmit and receive coil sensitivities (B1{plus minus}), which vary per subject. This adds intersubject variance, which could mask any effect between groups. No quality metrics (SNR or uncertainty estimates) are given for the MRI metrics.</p>
<p>Spectroscopic imaging was conducted 16 s after injection. Given the high heart rate of a mouse, measures of perfusion (using urea) could , therefore, be considered in a steady state, lowering sensitivity to any changes in perfusion or metabolite delivery. Furthermore, it is unclear how any changes in BBB permeability would manifest with the relatively low spatial resolution of MRSI. Would signal always be dominated by vascular compartments?</p>
<p>There is no apparent attempt to understand if an immune response occurs at this chronic time point. Macrophages are glycolytic and could affect the pyruvate measurement. Furthermore, is there any evidence for cellular changes in this model, namely density, cell type fraction, or microstructure? Are there any expected changes in glucose uptake?</p>
<p>There is no information or references provided for the accuracy or precision of the postmortem assays or their correlation with in vivo processes. What is the effect of cell density changes after injury on the assay kits?</p>
<p>The proposed interpretation of T1 as a measure of oxidative stress would seem to ignore the many confounding interpretations of T1.</p>
<p>Aims and impact:</p>
<p>In summary, the authors broadly achieve one aim, which is to find that HP 13C measured lac/pyruvate is a biomarker for the chronic effects of rTBI in a mouse model. As the authors themselves highlight in the discussion, the interpretation of this finding is tricky alongside their post-mortem assay results. The MR imaging in this work seems inconclusive, given the potential for inter-subject variance in the normalisation method.</p>
<p>The work, therefore, continues to highlight that HP 13C MRSI is a highly promising avenue of investigation to identify, characterise, and understand traumatic brain injury. It suggests that HP 13C MRSI is more promising in this sense than some standard MRI contrasts. The work currently fails to convincingly interpret the HP 13C MR results in conjunction with the other metrics.</p>
</body>
</sub-article>
</article>